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SUMMARY 1 
Immunity to Pasteurella haemolytica was studied 
using models of P. haemolytica infection in both lambs and 
mice. 
Immunisation of specific pathogen-free lambs with a 
. vaccine containing a sodium salicylate extract of 
P. haemolytica type Al protected against challenge with 
P. haemolytica type Al, superimposed upon infection with 
parainfluenza type 3 virus. Lymphocyte transformation 
responses of peripheral blood leucocytes from vaccinated 
lambs increased markedly after challenge. The passive 
transfer of hyperimmune serum, produced by repeated 
vaccination of lambs with the säure vaccine, did not protect 
recipients from challenge. Serum from vaccinated lambs 
had a bacteriostatic effect upon P. haemolytica in vitro, 
although this serum failed to facilitate phagocytosis of 
P. haemolytica by alveolar macrophages in vitro. 
w 
Two models of P. haemolytica infection in mice were 
investigated. Intranasal infection of mice with P. haemo- 
llytica caused lesions in the lung 3 days later. Bacteria 
were cleared from the'lung by 48 hours after infection, and 
because similar lesions were produced bj the introduction of 
2 
heat-killed P. haemolytica, this model was not investigated 
further. 
P. haemolytica introduced to mice intraperitoneally in 
gastric mucin multiplied in the liver and spleen. The 
effect of vaccination with various extracts of P. haemoly-" 
tica upon growth in the liver was investigated. Vaccines 
containing sodium salicylate extracts of P. haemolytica 
types Al, A6, A8, All and T10 protected against challenge 
with homologous strains, -and little cross-protection between 
the various strains was observed. 
The model of intraperitoneal challenge of mice was used 
to investigate the commercial Pasteurella vaccine, Carovax. 
When given 12 or 24 hours before challenge, the vaccine 
protected against challenge with P. haemolytica type Al, 
and also Escherichia coli, indicating that protection was 
non-specific. When the vaccine was given 1 hour, 48 hours, 
7 days or 14 days before challenge with. P. haemolytica 
type Al, no such protection was observed. 
An enzyme-linked immunosorbent assay was developed for 
detection of antibodies to P. haemolytica in the sera of 
vaccinated mice. There was considerable cross-reaction 
between sera from mice immunised with sodium salicylate 
extracts of the different types of P. haemolytica. 
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6 
NB = nutrient broth 
ND = not done 
n. t. = not treated 
OD optical density 
PBS phosphate-buffered saline 
PBS/Tween phosphate-buffered saline containing 0.05% 
Tween 20 
P13 = parainfluenza type 3 
PVP polyvinyl pyrrolidone 
RBC red blood cells 
SC subcutaneous 
SE standard error 
SED. standard error of difference of means 
S. I. = stimulation index 
SPF = specific pathogen free 
SSE = sodium salicylate extract 
V = vaccinate 
GENERAL INTRODUCTION ý 
Pneumonia is an important lesion in a high proportion 
of sheep necropsied in the United Kingdom (Veterinary 
Investigation Diagnosis. Analysis II Report, 1977). 
Although the figures quoted in the report may not 
accurately reflect the total losses to the industry from 
this cause, it is likely that the disease is of some 
considerable economic consequence. The pneumonia, at 
least in its terminal stages, is commonly associated with 
bacteria, and the organism which may be isolated from the 
lungs with the greatest frequency is Pasteurella 
haemölytica. Organisms with similar characteristics may 
be isolated from a variety of other clinical conditions 
of sheep, the most important of which is a septicaem c 
disease. P. haemolytica is not restricted to sheep, and 
the organism is also associated with pneumonia or 
"transit fever" of cattle in both North America and Europe 
(Carter, 1954). 
The characteristics of P. haemolytica have been 
extensively studied and the species is subdivided into 
types on the basis of certain biochemical and antigenic 
features. Particular types of the organism are 
predominantly associated with pneumon'. a and other types 
8 
with septicaemia in sheep. This has been extensively 
reviewed recently (Carter, 1967; Thompson, 1973) and only 
the salient points will. be considered at a later point in 
this introduction. 
Vaccines aimed at prevention of pasteurellosis are 
available in this country*, but nevertheless P. haemolytica 
is still implicated in many outbreaks of disease. This 
indicates that either the use or uptake of the vaccine is 
inadequate, or that the immunising powers of current 
vaccines are insufficient to protect against the field 
disease. The latter possibility is supported by the 
general unsatisfactory nature of vaccine trials (Pyke, 
1966). 
Development of P. haemolytica vaccines has been 
hampered in the past by the absence of a suitable system 
to reproduce the disease either in sheep or in laboratory 
*Carovax, Wellcome Foundation Ltd., Beckenham, England; 
Ovivac-P, Pasticidin, Hoechst Pharmaceuticals, Hounslow, 
Middlesex, England. 
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animals. This has not only hindered progress towards 
satisfactory immunisation, but it has also prevented 
development of a full understanding of the immune 
mechanisms involved in protection against the organism. 
These aspects will also be discusscý in this introduction. 
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Characterisation of P. haemoiytica 
The taxon, P. haemolytica was introduced by Newsom 
and Cross (1932) to designate an organism associated with 
disease in cattle, although the first description of the 
organism had appeared eleven years earlier (Jones, 1921). 
In a study of bacteria isolated from cases of bovine 
pneumonia Jones distinguished three groups of organisms 
by the criteria of colonial morphology, biochemical and 
serological reactions. Group I organisms were short, 
non-motile, gram-negative bipolar cocco-bacilli. 
Colonies on blood agar were flat and translucent, 3-5 mm 
in diameter after 48 hours incubation, and were 
haemolytic. Cultures were indole-negative. These 
organisms, and Group II and III organisms, which were 
indole-positive and non. -haemolytic, were referred to as 
Bacillus bovisepticus. Similar organisms, isolated 
from pneumonic lambs were named Pasteurella ovise tý icum 
(Spray, 1923). In a study of gram-negative cocco- 
bacilli isolated from sheep and cattle, Newsom and Cross 
(1932) defined a "typical" and an "atypical" group. The 
"typical" group was similar to Groups II and III of 
Jones (1921). The "atypical" haemolytic group resembled 
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Jones' Group I and was designated Pasteurella haemolytica. 
(The "typical" group has since been classified as 
Pasteurella multocida). 
P. haemolytica is defined as a gram-negative, non- 
motile rod, which is aerobic and facultatively anaerobic. 
it is oxidase-positive and attacks sugars by fermentation, 
but does not produce gas (Cowan and Steel, 1974). 
Cultural reactions of P. haemolytica are diverse, and in 
view of this, certain criteria-for identification of the 
species were adopted by Biberstein, Gills and Knight 
(1960). These are listed here, in diminishing order of 
importance. 
1. Haemolysis on blood agar. The extent of 
haemolysis varies considerably from strain to 
strain, and sometimes is only detectable 
directly underneath the colonies. However, 
haemolysis is a useful feature by which 
P. haemolytica and P. multocida can be 
distinguished, as the latter is non-haemolytic. 
i ,2 
2. Absence of indole production. This is a 
uniform characteristic of P. baemolytica, 
in contrast to P. multecida, which is 
indole-positive. 
3. Growth on McConkey's agar. P. haemolytica 
grows well on McConkey's agar, wbereas 
P. multocida does not. 
4. Failure to reduce methylene blue milk. 
In addition to these characteristics, P. haemolytica 
is"oxidase-positive, a useful feature which distinguishes 
it from most of the Enterobacteriaceae, which are oxidase- 
negative. 
Satisfactory fermentation reactions with these 
bacteria are difficult to achieve, as growth on many 
fermentation media is poor, and results obtained are 
often inconclusive (Thompson, 1973). Smith (1959 B) 
classified strains of P. haemolytica from sheep into two 
biotypes, designated A and T. Biotype A strains appeared 
to be associated with pneumonia, and biotype T strains 
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with septicaemia of lambs. These biotypes were later 
characterised further on the basis of colonial morphology, 
fermentation reactions, growth curves and sensitivities 
to antibiotics (Smith, 1961). Biotype A strains formed 
small grey colonies on sheep blood agar, and fermented 
arabinose within 7 days, but not trehalose by 10 days, 
while biotype T strains formed larger colonies with 
brownish centres and fermented trehalose within 2 days, 
but not arabinose within 10 days. Biotype A strains 
lost viability rapidly in ageing broth cultures and were- 
more sensitive to penicillin and tetracycline than 
biotype T strains. 
A variety of methods have been used in attempts to 
subdivide P. haemolytica serologically. Early studies 
established that P. haemolytica was antigenically distinct 
from P. multoci. da (Jones, 1921; Newsom and Cross, 1932), 
whereas studies concerned mainly with P. haemolytica 
revealed one (Tweed and Edington, 1930), two (Florent and 
Godbille, 1950), or three serotypes (Montgomerie, 
Bosworth and Glover, 1938), by means of agglutination 
reactions. Biberstein, Gills and Knight (1960) attempted 
to subdivide the species an the basis of somatic antigens 
6 
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by direct agglutination tests, using autoclaved bacterial 
cells. Strains from sheep and cattle derived from a 
variety of clinical conditions, pneumonia, septicaemia, 
arthritis and mastitis, and from the nasopharynx of 
healthy individuals, were examined by this method. These 
strains, which would be expected to cover a wide spectrum 
of types of P. haemolytica, fell into two main groups 
(I and II) on the basis of these and additional fermentat- 
ion tests. 
P. haemolytica possesses a soluble, heat-stable 
capsular component, which has been used successfully to 
subdivide the species into several serotypes. An 
indirect haemagglutination (IHA) test, using this as 
antigen was developed by Biberstein, Gills and Knight 
(1960). The test involved sensitisation of bovine red 
blood cells (bovine RBC) with soluble antigens from 
P. haemolytica and their agglutination with antisera 
raised in rabbits against selected strains. This IRA 
reaction divided the species into eleven sharply defined 
types, and cross-reactions between types were minimal. 
A variety of other IAA tests have also been developed 
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to subdivide P. haemolytica. Carter (1956) attempted to 
classify 51 strains of P. haemoiytica isolated from cases 
of shipping fever in Canada. T'e soluble polysaccharide 
from these strains was adsorbed onto type 0 human red 
cells (HuRBC) which were then agglutinated in the presence 
of dilutions of specific immune sera raised against the 
test strains in rabbits. All strains were found to be 
serologically homogeneous and totally distinct from 
multocida in this study. This test was modified by 
Cameron (1966). Guinea pig red cells were used instead 
of HuRBC, and it was found that clearer agglutination 
patterns were obtained if the red cells, after treatment 
with antigen, were suspended in dilute normal rabbit 
plasma. In this study, the IHÄ test was employed to 
determine the titres of sera from sheep immunised with a 
known strain of P. haemolytica, rather than to type 
unknown strains. 
The IHA test of Biberstein, Gills and Knight (1960) 
has been widely used. As larger numbers of strains were 
typed, it became apparent that occasionally a batch of 
antigen prepared from a particular strain of P. haemolytica 
would be agglutinated by 2 or 3 antisera (Biberstein, 1965). 
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In some cases this was due to a mixture of types in the 
original culture, but in others there were cross-reactions 
between different types. It was demonstrated that these 
were due to minor antigens, which did not interfere with 
the typing procedure. The technique was modified by 
Biberstein and Thompson (1966) who substituted Perspex 
trays of 1 ml capacity for the Wasserman tubes previously 
used. A 12th serotype was discovered in this study. 
Later, the test was adapted to a microtitre system 
(Shreeve, Biberstein and Thompson, 1972). 
Smith's discovery of the biotype A and biotype T 
strains of P. haemolytica seemed to relate to the two 
divisions of the species later suggested by Biberstein, 
Gills and Knight (1960). To confirm this, a selection of 
strains of P. haemolytica, representing each serotype was 
classified as either biotype A or T on the basis of fermen- 
tation tests (Biberstein and Gills, 1962). A reasonable 
degree of correlation was found between the two methods 
of classification. In general, Smith'. s biotype A (1959 B) 
correspond to Group I. of Biberstein, Gills and Knight 
(1960) and biotype T corresponded to Group IT. An 
exception was serotype 2, which was classified as 
biotype A by Smith, and is included in Group II of " 
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Biberstein, Gills and Knight (1960). Serotypes 1,2,5, 
6,7,8,9,11 and 12 are now considered to belong to 
biotype A and serotypes 3,4 and ?. U to biotype T. 
An investigation of nucleic a^-. d homologies between 
biotypes A and T of P. haemolytica showed a high degree of 
homology between two biotype A strains, but the homology 
between a biotype A and a biotype T strain (30-50%) was 
less than that often obtained for interspecies hybridi- 
sations (Biberstein and Francis, 1968). Electrophoresis 
in polyacrylamide gels of the constituent proteins of each 
serotype of P. haemolytica gave patterns which could be 
used to subdivide the species into two groups which broadly 
corresponded to the biotypes A and T (Thompson and Mould, 
1975). The available evidence suggests that the subdi- 
vision of P. haemolytica into these two groups is a valid 
one, and some workers feel that there are grounds for 
regarding the biotypes as separate species (Smith and Thal, 
1965). This has not been resolved, so for the sake of 
brevity strains of P. haemolytica will be referred to as 
'type Al" and "Type T3 ", etc. 
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The distribution of P. haemolytica types amongst healthy 
sheep 
The recognition of different types has assisted the 
study of epidemiology of P. haemolytica in healthy flocks 
of sheep. P. haemolytica has been isolated frequently 
from the upper respiratory tract of apparently healthy 
sheep (Biberstein and Thompson, 1966; Biberstein, Shreeve 
and Thompson, 1970). A survey of normal flocks showed 
that the same types occur in the USA and Great Britain, 
with the possible exception of type A12, which was not 
identified in'the USA (Biberstein and Thompson, 1966). 
Type A2 strains were predominant in Great Britain, 
whereas some types well represented in the USA, such as 
5,8 and 9 were apparently rare in Great Britain. Type A 
strains outnumbered type T strains in the nasopharynx of 
healthy sheep. In contrast, P. haemolytica was isolated 
from the tonsils of 95 of 100 adult sheep, 65% of these 
isolates being type T (Gilmour, Thompson and Fraser, 1974). 
Sixty-four of 100 nasopharyngeal swabs from these sheep 
yielded P. haemolytica and only 6% of these were of type T. 
A 12 month survey showed that the proportion of sheep 
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carrying P. haemolytica intranasally increased markedly 
in late autumn and spring (Biberstein, Shreeve and 
Thompson, 1970). Prevalence of the different types 
varied from month to month, and flock to flock. There 
was no si:, 1p1e relationship between incidence of carriers 
and weather changes. It is interesting that, although 
the flocks in this survey remained healthy, the two peak 
periods of nasal carriage of P. haemolytica correlated 
with the known pattern of enzootic pneumonia in the 
region. 
Young lambs reared with their ewes acquired an 
increasing number of types as they grew older (Shreeve 
and Thompson, 1970). The. first typable colonies were 
detected 48 hours after birth. In contrast, few typable 
strains were recovered from lambs removed from their dams 
at birth, and it appears likely that intimate and prolonged 
contact with adult sheep may facilitate colonisation of 
the lamb with P. haemolytica. 
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Diseases of sheep associated with P. haemolytica 
1. Septicaemia 
Fatal septicaemia of lambs, in which death is sudden 
and often not preceded by other symptoms, was first 
described by Stamp, Watt and Thomlinson (1955). Although 
no quantitative epidemiological study of septicaemic 
pasteurellosis has been made, this disease is an important 
cause of death. 
Post-mortem findings include congestion of the trachea 
and bronchi with blood-stained, frothy fluid, distension of 
the capillaries and venules of te lung, with oe ia in the 
alveoli and interlobular septa. However, the lungs are 
seldom pneumonic. Lymph nodes are enlarged and haemorr- 
hagic. Haemorrhagic exudative inflammation is found on 
the abomasal mucosa, and there is blood'splashing on the 
visceral peritoneum, in the neck and beneath the parietal 
pleura. P. haemolytica can be cultured in large numbers 
from the heart blood, lung, liver, kidneys and spleen. 
Generalised septicaemia of lambs under three months of age 
is predominantly associated with type A strains (Smith, 
1960 A; Biberstein and Thompson, 1966). In contrast, 
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100% of septicaemias in lambs over three months of age are 
due to type T strains (Biberstein and Thompson, 1966). 
Type T strains of P. haemolytica are normally found 
as commensals in the tonsils of healthy sheep (Gilmour, 
Thompson and Fraser, 1974), and no convincing explanation 
has yet been offered as to why this organism should 
suddenly become pathogenic. The syndrome occurs in all 
ages of sheep, at all times of the year, but would appear 
to be more common in hoggs during September, October and 
November (Gilmour, 1978). This period coincides with 
movement of sheep from high to low ground pastures for 
the winter or the start of folding on rape or turnips. 
The first deaths often occur within a few days of a flock 
being moved. Deaths are sporadic and stop after several 
days. The mortality rate may be as high as 20% and, 
surprisingly, deaths tend to be amongst sheep in the best 
of condition. The factors which predispose sheep to this 
condition have yet to be identified. The primary site of 
invasion of P. haemolytica is not known. It has been 
suggested that P. haemolytica may enter the blood via the 
respiratory tract, perhaps as a secondary invader, but 
Stamp, Watt and Thomlinson (1955) found no evidence to 
support this. In several cases where pneumonic lesions 
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were present, it was considered that these were secondary 
to bacterial thrombi in the pulmonary vessels. 
2. Pneumonia 
One of the earliest outbreaks of pneumonic pasteurel- 
losis of sheep to be described was in Wales (Montgomerie, 
Bosworth and Glover, 1938). These authors referred to 
the disease as "enzootic pneumonia", which by strict 
definition means a pneumonia of low incidence, but which 
is constantly present in a given community, so the term 
is not a specific one. However, in this country 
"enzootic pneumonia" has come to be the term applied to 
pneumonia of sheep associated with P. haemolytica. 
Outbreaks of acute pneumonic pasteurellosis usually 
begin suddenly, with sheep dying or becoming severely ill 
with obvious respiratory disease. Other sheep may exhibit 
signs of mild respiratory involvement, such as coughing 
and oculonasal discharge. Mortality during such. acute 
outbreaks rarely exceeds 10% (Gilmour, 1978). In the 
acute phase of the disease, pleurisy and pericarditis are 
usually present, with a greenish gelatinous exudate over 
the pericardium, extending into the anterior mediastinum. 
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Also, large volumes of straw-coloured pleural fluid with 
fibrin clots are observed. In hyperacute cases the 
lungs arc enlarged and oedematous with large bright red 
or purple areas. Such areas are solid, oedematous and 
haemorrhag-c. 
Histologically, the lungs show necrosis of the 
alveoli and the alveolar spaces are filled with fluid 
and abundant gram-negative cocco-bacilli. The inter- 
lobular septa are widened'by oedema, and the capillaries 
are distended with fluid and red blood cells. Spindle- 
shaped cells with basophilic nuclei, called "oat cells" 
are present in the lung lesions and are a characteristic 
feature of this pneumonia.. Large numbers of these cells 
surround areas containing necrotic alveoli. 
Pneumonic pasteurellosis is almost exclusively 
associated with type A strains of P. haemolytica (Smith, 
1961), which are found in numbers exceeding 107 per gram 
of tissue in the lung lesions. 
The production of experimental pneumonia in sheep 
has proved to be difficult.. Dungal (1931) produced typi- 
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cal pneumonia in three sheep by intratracheal (IT) 
inoculation of 9 hour cultures of P. haemolytica. One 
animal showed symptoms, while pneumonia in all three was 
demonstrated at necropsy. Salisbury (1957) failed to 
reproduce pneumonia by inoculation of infected material 
by a variety of routes. Partial success in transmitting 
pneumonia with infected chorioallantoic suspension along 
with P. haemolytica culture was achieved by Downey (1957). 
Intrabronchial inoculation of large numbers of 
P. haemolytica type A, which had been cultured in the 
peritoneal cavities of mice, produced pulmonary infections 
resembling the acute form of pneumonic pasteurellosis 
(Smith, 1964). Intrabronchial inoculation of similar 
numbers of heat-killed P. haemolytica did not produce 
lesions. 
The strains which cause'disease normally reside as 
commensals in the nasopharynx. Therefore, there must be 
factors which predispose sheep to disease. These are not 
fully characterised, but one suggestion is that prior 
infection with Parainfluenza type 3 (P13) virus may render 
sheep more susceptible to invasion of the lungs with 
P. haemolytica. Experimental*pneumor. ic pasteurellosis in 
specific pathogen free (SPF) lambs. has been-successfully 
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produced by the establishment of a P13 virus infection 
prior to exposure to an aerosol of P. haemolytica (Sharp, 
Gilmour, Thompson and Rushton, 1978). This finding lends 
support to the. theory that P13 virus infection might be 
an important predisposing factor in the etiology of 
pneumonic pasteurellosis. However, it is recognised 
that other factors may well exist which play an important 
part in rendering sheep susceptible to P. haemolytica 
infection. Synergism between respiratory viruses and 
bacteria in the respiratory tract is well documented, and 
has been reviewed by Loosli (1968). 
The question of whether a single factor or many 
factors predispose sheep to pasteurellosis is important. 
If one factor only compromises the host and allows 
P. haemolytica to invade, there would be little place for 
a P. haemolytica vaccine. Control of the disease could 
be more effectively achieved by vaccination against the 
primary infecting agent, or, if an environmental factor 
were involved, by its exclusion by management. However, 
if there were many factors which predispose sheep to 
pasteurellosis, an effective pasteurella vaccine would be 
most useful, as control of the disease by vaccination to 
a single agent would be easier than attempting to exclude 
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a multiplicity of other factors. 
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Requirements for a suitable vaccine against P. haemolytica 
and methods for study of vaccine efficacy 
Commercial vaccines against pasteurellosis are avail- 
able, but these are of questionable value (Gilmour, 1978). 
Despite their use, pasteurellosis is widespread. These 
vaccines contain only a limited number of types of 
P. haemolytica, and there is as yet no evidence to suggest 
that cross-protection between the different types occurs. 
Field trials of vaccine preparations are difficult to 
assess, due to the sporadic nature of the disease. Many 
attempts have been made to reproduce pneumonic pasteurell- 
osis experimentally (Dungal, 1931; Salisbury, 1957; Downey, 
1957), and it is only recently that this has been consis- 
tently successful. Due to the ubiquitous distribution of 
the organism, the vast majority of sheep have prior 
experience of it, and have antibodies in their serum to 
P. haemolytica detectable by the IHA test (Gilmour, 
personal communication). Such sheep may therefore be 
unsuitable for experimental purposes. Laboratory animals 
are not susceptible to P haemolytica infection which has 
made it difficult to use these species either for initial 
vaccine evaluation or for determination of the immunologi- 
cal features of the disease in these animals. 
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Experimental reproduction of pasteurellosis in sheep 
1. Septicaemia 
Successful reproduction of P. haemolytica septicaemia 
in lambs was achieved by the intravenous (IV) injection of 
cultures derived from clinical cases of septicaemia 
(Stamp, Watt and Thomlinson, 1955). Intraperitoneal (IP) 
injection of P. haemolytica type A cultures into three 
week old lambs resulted in death within 12 hours from 
acute fibrinous peritonitis (Smith, 1960 A). Adult sheep 
were not susceptible to doses which killed young lambs. 
109.9 colony forming units (cfu) of P. haemolytica type T 
given IV to both 6 month old lambs and adult sheep resul- 
ted in death (Smith, 1960 B). Lambs which survived 
challenge with smaller numbers of organisms had positive 
blood cultures at 24 hours, whereas P. haemol tics was 
recovered from only one adult sheep. However, the 
number of organisms required to produce septicaemia is 
very large especially in adult sheep, and is only slightly 
less than the number of dead bacteria which would cause 
death. This tends to suggest that hitherto undefined 
factors are involved in the development of the field 
disease. As septicaemia often follows a change of 
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pasture, it was thought that acidosis, caused by the 
sudden change of diet, may be a predisposing factor. 
For this reason, a state of acidosis was induced in sheep 
by dietary manipulation, prior to challenge with 
P. haemolytica. These sheep were no more susceptible to 
the disease, implying that acidosis alone is not respon- 
sible (Gilmour, personal communication). 
2. Pneumonia 
Early attempts to reproduce pneumonia in sheep with 
P. haemolytica achieved only limited success (Dungal, 1931; 
Salisbury, 1957; Downey, 1957). The most promising method 
was that of Smith (1964) which involved intrabronchial 
inoculation of large numbers of P. haemolytica type A. 
Pulmonary infections similar to acute pneumonic pasteure- 
llosis were produced. 
Most conventionally reared sheep have circulating 
antibodies to P. haemolytica, which may affect the 
consistent reproduction of the disease. ' Serum immunoglo- 
bulin levels in newborn lambs prior to sucking are generally 
very low, indicating that there is little or no transfer of 
immunoglobulin across the placenta (Smith, Wells, Burrells 
4 
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and Dawson, 1976). Therefore, lanbs which have not 
received colostrum might be expected to give reproducible 
results in challenge experiments. Five of ten SPF lambs 
exposed to an aerosol of P. haemolytica type Al developed 
pneumonia 4. ndistinguishable from natural pneumonic 
pasteurellosis (Gilmour, Thompson, Smith and Angus, 1975). 
P13 virus has been associated with ovine respiratory 
disease and after experimental inoculation, produces a 
transient mild disease (Hore and Stevenson, 1969). SPF lambs 
inoculated with both P13 virus and P. haemolytica consistently 
develop severe clinical disease in a high proportion of 
animals (Sharp, Gilmour, Thompson and Rushton, 1978). 
The illness and lung'lesions in lambs which received both 
agents were more severe than in lambs inoculated with 
either agent alone. Previous combined infections with 
P13 virus and P. haemolytica were less severe and less 
consistent (Biberstein, Shreeve, Angus and Thompson, 1971). 
The success of the method of Sharp, Gilmour, Thompson and 
Rushton (1978) was attributed to the use of SPF lambs. 
Lambs not hysterectomy-derived and reared in isolation 
may well have encountered P. haemolytica before inoculat- 
ion. The time interval between P13 virus infection and 
challenge may also be important. Three days elapsed 
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between viral and bacterial challenge in the method of 
Biberstein, Shreeve, Angus and Thompson (1971) whereas 
the interval was 7 days in the method of Sharp, Gilmour, 
Thompson and Rushton (1978). 
This method has been successfully used for the 
investigation of P. haemolytica vaccine preparations 
(Gilmour, Martin, Sharp, Thompson and Wells, 1979). In 
a series of experiments, the immunogenicity of sodium 
salicylate extracts (SSE) of P, haemolytica was tested. 
These experiments will be discussed more fully elsewhere 
in this thesis. . Briefly, protection was demonstrated 
against challenge with the homologous strain when the 
antigen was an extract of either P. haemolytica type Al 
or A6. A heat-killed preparation (HKO) of P. haemolytica 
type A2 afforded some protection in one experiment, but in 
another, where the vaccine contained extracts of types Al 
and A6, and HKO of type A2 no protection against challenge 
with P. haemolytica type A2 was demonstrated. This model 
of infection has proved extremely useful for the study of 
L. haemolytica vaccines. Later in this thesis, experiments 
are described in which this model of infection was used to 
investigate the mechanisms of immunity to 'P. haemolytica 
in sheep pneumonia. 
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Models of infection with P. haemolytica in 
laboratory animals 
Experiments with sheep, in particular SPF lambs, are 
costly and the number of animals available is limited and 
seasonal. A model of P. haemolytica infection in a 
laboratory animal would have the advantages of relative 
low cost and ready availability of greater numbers of 
experimental animals throughout the year. Unfortunately, 
infection of small animals with P. haemolytica has proved 
difficult. 
Many workers have tried in vain to infect small ania1als 
by various routes. -These include cats, dogs, hens, 
pigeons, rabbits and guinea pigs (Dungal, 1931; Lovell and 
Hughes, 1935; Beveridge, 1937.; Montgomerie, Bosworth and 
Glover, 1938). 2 haemolytica is also relatively non- 
pathogenic for mice, unless very large numbers of organisms 
are administered, and the lethal effects may well be due 
to the direct action of the endotoxin present in such a 
large inoculum (Smith, 1958). 
In contrast, the related organism, P. multocida is 
exceptionally virulent for mice. When introduced by 
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various routes, the organism grows rapidly and causes 
fatal septicaemia (Collins, 1973). The LD50 of 
P. multocida strain 5A was shown to be 1-2 organisms when 
given IV, IP or-by the subcutaneous (SC) route. Mice 
vaccinated IV with two doses of a heat-killed P. multocida 
suspension were fully protected against challenge 7 days 
later by IV, IP and SC routes. Partial protection 
against aerogenic challenge was also achieved (Collins 
and Woolcock, 1976). Passive immunisation studies 
showed that protection was humorally mediated. The 
manner by which the immune host eliminates this extremely 
virulent organism has been studied by following the rate 
of growth of P. multocida in mice given various treatments 
and challenged by a variety of routes. 
Another member of the genus Pasteurella, Pasteurella 
pneumotropica, is a natural infectious agent of mice and is 
often isolated from the respiratory tract. Its incidence 
in mouse colonies is high, but mice can carry the organism 
and show no signs of clinical disease (Hoag, Wetmore, 
Rogers and Meier, 1962). However, P. pneumotropica is a 
potential pulmonary pathogen, and is frequently implicated 
in outbreaks c' pneumonia in mouse colonies (Brennan, 
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Fritz and Flynn, 1965; Jawetz, 1950). Mice challenged 
by aerosol with P. pneumotropica alone eliminated the 
organi. an from the lungs within 7 hours (Jakab and Dick, 
1973). In contrast, intrapulmonary killing of 
P. pneumotropica was delayed in mice which. had been 
previously infected with Sendai virus, the maximum effect 
being achieved when the interval between virus infection 
and challenge with P. pneumotropica was 6 days. It was 
shown that previous immunisation with Sendai virus 
completely prevented subsequent virus infection, and thus 
the synergistic effect. This model has proved useful in 
the investigation of synergism between viral and bacterial 
infections. 
Smith (1958) developed two successful methods of 
challenge with P. haemolytica in mice. Intracerebral 
inoculation of organisms in casein hydrolysate solution 
resulted in multiplication of the'organisms and death. 
The bacteria were usually confined to the brain and 
meninges, and the susceptibility of individual mice 
varied considerably. Brain trauma induced in mice by 
intracerebral inoculation of starch-saline solution, in 
conjunction with TV infection with P. haemolytica gave 
100% mortality, provided a suitable challenge dose was used. 
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To establish infection in mice with P. haemolytica 
given by the intraperitoneal route, very large numbers of 
organisms are needed. This can be considerably reduced 
if gastric mucin is incorporated into the inoculum (Smith, 
1958). 
It is accepted that mucins can enhance the virulence 
of organisms which are weakly or non-pathogenic (Reviewed 
by Olitzki, 1948). Examples include type III 
pneumococcus and Klebsiella pneumonia injected IP into 
mice. Bacillus anthracis injected IP into rats (Nungester, 
Jourdonais and Wolf, 1936) and Candida albicans injected 
IP into mice (Scherr, 1953). Although the viscosity of 
mucin evidently has a physically protective role towards 
the bacteria, other factors which act upon the host, rather 
than upon the organism, are probably of equal, if not 
greater importance. It has been suggested that mucin. 
depletes serum of properdin, a protein which plays an 
important role in the alternative pathway of complement 
activation, thus lowering the resistance of the animal 
to infection. However, an investigation by DeWitt (1958) 
showed that there was no direct correlation between anti- 
properdin activity in vitro and-the infection-promoting 
ability of mucins. 
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The IP infection of mice with P. haemolytica 
incorporated into gastric mucin has proved to be a most 
valuable model for the study of this organism. Deaths 
occur within 48 hours of infection, after the development 
of septicaemia. Smith (1958) demonstrated that mice 
could be passively protected against infection with 
rabbit antisera, and this was later developed into the 
"passive immunity test". By injecting mice IP with sera 
from sheep which have been vaccinated against P. haemoly- 
tica and then challenging them, some measure of the 
protective capacity of the sera can be determined 
(Gilmour, personal communication). Mice can also be 
protected against challenge by active immunisation (Smith, 
1959 A). Biberstein and Thompson (1965) used this model 
to investigate the roles of capsular and somatic antigens 
in immunity to P. haemolytica. Mice were vaccinated with 
bacterins from strains of P. haemolytica which possessed 
various combinations of somatic and capsular antigens, and 
were subsequently challenged with homologous and heterolo- 
gous strains. The resulting pattern of protection 
suggested that capsular antigens play the major role in 
determining the specificity of the immunity conferred, 
with the somatic antigens only secondarily involved. 
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However, a later report (Knight, Biberstein and Allison, 
1969), in which similar experiments were undertaken with 
a larger number of animals, cast : doubt upon some of these 
original conclusions. The importance of the capsular 
antigens was confirmed, but anomalies were found. In 
two experiments, the highest degree of protection was 
shown when the immunising and challenging strains shared 
no demonstrable antigenic factors. It was suggested that 
there may exist factors other than the capsular and 
somatic antigens demonstrable by simple laboratory 
typing, which determine. the specificity of immunity. 
A model for intranasal (IN) infection of mice with 
P. haenzolytica has recently been developed (Rushton, 1978). 
Three days after IN inoculation of 106'6-107.6 cfu, under 
anaesthesia, a non-fatal pneumonia developed. Investi- 
gations using this model will be described later in this 
thesis. 
The pathology and bacteriology of both septicaemia 
and pneumonia of sheep associated with P. haemolytica are 
well characterised. However, the immune mechanisms of 
the sheep to this organism are at present ill-defined, and 
an effective vaccine against pasteurellosis has yet to be 
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produced. The work to be described in this thesis is an 
investigation into some aspects of this problem, using 
models of infection with P. haemolytica in both sheep and 
mice, in an attempt to elucidate the important features 
of the immune response to P. haemolytica. 
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Bacteriological techniques 
Strains of P. haemol tics 
All strains of P. haemolytica used in this study were 
of ovine origin. Strains of types Al, A2, A5, A6, A7, 
A8, A9 and All had been isolated from cases of sheep 
pneumonia. Strains of types T3, T4 and T10 were from 
cases of septicaemia in lambs, and the strain of type A12 
was originally isolated from a case of mastitis in a ewe. 
These strains were stored either freeze-dried, or in 0.5 ml 
aliquots of broth culture at -70°C. When required, an 
aliquot was removed from storage and inoculated into 50 ml 
nutrient broth (NB - Oxoia* CM67) and incubated overnight 
at 370C. The culture was streaked onto sheep blood agar 
(Oxoid* CM55, with 15% citrated ovine blood) to check 
purity, and single colonies were used as inocula for 
further broth cultures. 
Strain of Escherichia coli 
The strain of E. coli, B188, was kindly provided by 
Dr. H. Williams Smith. It was of bovine origin, 
*Oxoid Ltd, Basingstoke, Hampshire, England. 
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serotype 078: K80: 9-, and was invasive but did not produce 
enterotoxin (Smith and Huggins, 1976). E. coli was 
stored in a similar manner to P. haemolytica. 
Enumeration of bacteria 
Viable counts were carried out by the method of 
Miles, Misra and Irwin (1938). Appropriate 10-fold 
dilutions were made in peptone water (Oxoid L37) and 
duplicate 20 pl samples of these spotted onto sheep blood 
agar plates. Viable counts were read after incubation 
overnight at 37 
°C. 
A method was devised whereby the number of organisms 
in a. suspension could be estimated by measuring absorbance 
in a colorimeter (Vitatron UPS Photometer). Each strain 
of P. haemolytica was inoculated into 300 ml of NB and 
incubated at 370C for 18 hours, washed twice in 0.15 M NaCl, 
and a range of dilutions were made which gave optical 
densities (OD) to cover the range of the colorimeter. 
The OD of the suspensions at 400 nm were measured. Viable 
counts were also performed on these preparations and. 
standard curves of numbers of viable organisms against OD 
were plotted (Figs. 1-4). These graphs allowed. inocula 
Figure 1 Standard curves of P. haemolytica types 
A6, A7 and AB against OD at 400nm 
Figure 2 Standard curves of P. haemolytica types 
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Figure 3 Standard curves of P. haemolytica types 
T3, T4 and T10 against OD at 400nm 
Figure 4 Standard curves of P. haemolytica types 
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41. 
to be adjusted to a determined 
density prior to admini- 
stration; viable counts were 
however obtained for all 
bacteria]. cultures standardised 
in this manner. 
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Laboratory animal techniques 
Mice 
Unless otherwise stated, mice used in experiments 
were of. the C57 black strain, bred at the Moredun 
Institute. Mice were of both sexes, and were 4-6 weeks 
old at the start of experimentation. Ten mice were 
housed in each cage. They were fed Modified Diet 41B 
(Laboratory Animal Diets, Herbert c. Styles (Bawdley)Ltd., 
for Oxoid Ltd. ), and given water ad lib. 
Inoculations 
1. Subcutaneous 
SC inoculations into mice were performed without 
anaesthesia. Mice were injected under the loose skin of 
the flank, using a 25 gauge needle. When more than one 
injection per mouse was required, the first was given on 
the right flank, and the second on the left. 
2. Intraperitoneal 
Mice were injected IP without anaesthesia, using a 
26 gauge needle. Injection was into the abdomen, slightly 
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to the left of the umbilicus. 
3. Intranasal 
Narcosis in mice was usually induced with halothane 
(Fluothane, ICI Ltd., Alderley Park, Cheshire), inhaled 
from saturated cotton wool beneath a false floor in a bell 
jar. When the level of narcosis was correct, mice were 
recumbent, insensitive and breathing evenly and shallowly. 
Mice were removed from the bell jar, were held upright 
and droplets of culture or saline (0.05 ml), which were 
inhaled rapidly, placed on the external pares. The 
mice recovered from anaesthesia within a few minutes. 
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Vaccines 
The experimental P. haemolytica vaccines used in much 
of this work were prepared from either SSE or HKO of 
various strains of P. haemolytica. 
Antigens 
1. Preparation of P. haemolytica SSE 
The extracts used in Chapters 1 and 2 were kindly 
provided by Dr. N. J. L. Gilmour. An aliquot of the 
required strain of P. haemolytica was removed from storage, 
inoculated into 50 ml nutrient broth and incubated at 
37°C overnight. The culture was checked for purity and 
serotype identity at this stage. Two pre-warmed 1.5 1 
volumes of nutrient broth were each inoculated with 15 ml 
of this culture and incubated with agitation at 37°C for 
6 hours. Viable counts were performed and the bacteria 
were sedimented by centrifugation at 12000 g for 20 minutes 
at 4°C. The cells were resuspended in 300 ml sterile 
1.0 M sodium salicylate solution and agitated at 370 C for 
3 hours. This procedure removed from the cells. the-outer 
layers. 
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The bacterial cells were removed by centrifugation 
0 
at 28000 g for 40 minutes at 4 C. The supernate was 
further clarified by centrifugation at 40000 g for 
0 
30 minutes at 4C (Spinco Model L, SW24 rotor). The 
extract was then dialysed for 48 hours against phosphate- 
saline buffer (0.02 M sodium phosphate, 0.03 M sodium 
chloride; pH 7.6) at 40C, concentrated by ultrafiltration 
through a Diaflo X100A membrane (Amicon Corp., Lexington, 
Mass., USA) to approximately 20 ml, then freeze-dried and 
stored until required. 
The method of sodium salicylate extraction was 
-modified slightly 
in vaccines used in Chapters 4 and 5. 
The organisms were grown, and sedimented by centrifugation. 
Thereafter the pellet was resuspended in 0.15 M saline and 
stored overnight. at 40C. The following morning, the cells 
were sedimented and resuspended in 300 ml M sodium 
salicylate solution and shaken at 370C for 3 hours. The 
extract was clarified as before, and concentrated to 
approximately 20 ml by ultrafiltration. A gelatinous 
deposit often present on the surface of the filter was 
removed by gently scraping with a glass rod, and added to 
the concentrate. The concentrated SSE, and an aliquot of 
the filtrate from ultrafiltration were each dialysed for 
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48 hours at 4°C against dilute phosphate-saline buffer 
and then dialysed against distilled water (DW) for 
72 hours. The dry weight of each preparation was 
determined, and. the extract was adjusted to 1.5 mg dry 
matter / ml, using the dialysed filtrate as diluent. 
Preparations were stored in small aliquots at -20°C until 
required. 
2. Preparation of heat-killed P. haemolytica 
Two 1.5 1 volumes of P. haemolytica were grown in the 
same manner as employed in the preparation of SSE. The 
organisms were sedimented by centrifugation, resuspended 
in r'iýy '1 volume of phosphate-buffered saline (PBS) 
pH 7.2 and incubated at 60°C in a water bath for 90 minu- 
tes. The preparation was then checked for sterility and 
freeze-dried. 
Preparation of vaccines 
The antigenicity of SSE of P. haemolytica type A6 in 
five adjuvants has been compared (Wells, Gilmour, Burrells 
and Thompson, 1979). Sheep were inoculated with antigen 
in either inc. 'mplete Freund's adjuvant (IFA), complete 
4 
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Freund's adjuvant (CFA), IFA containing water-soluble 
extract of Mycobacterium tuberculosis, an aluminium 
hydroxide gel adjuvant, or a vaccine in which the aluminium 
hydroxide gel was incorporated into IFA. The last-named 
vaccine induced significantly highe titres of antibody 
against P. haemolytica type A6 as measured by an IHA test 
than did any of the other vaccines. In addition, local 
reactions at the site of inoculation with this vaccine 
were not severe. For these reasons, most of the vaccines 
used in this study were prepared by adsorption of the 
antigen onto aluminium hydroxide, followed by emulsifi- 
cation in mineral oil. 
Adsorption of antigens onto aluminium hydroxide 
SSE (1.5 mg/ml) and HKO (10 mg/ml) were adsorbed 
onto an aluminium hydroxide gel adjuvant (A"ihydrogel, 
Superfos, Copenhagen, Denmark) after determination of the 
optimal dilution of Alhydrogel, according to the manufacu- 
rer's recommendations. When antigen is mixed with 
Alhydrogel at the optimal dilution, flocculation occurs. 
For each antigen a titration was carried out using a range 
of Alhydrogel concentrations with a standard amount of 
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in DW for this purpose and added to antigen in Wasserman 
tubes. After rapid mixing, the tubes were left at room 
temperature for 20-30 minutes. The first tube in the 
series in which a marked flocculation occurred, with a 
clear supernate, was taken as having the optimal 
concentration of Alhydrogel for that antigen (Plate 1). 
Emulsification of adsorbed antigen with mineral 
oil 
The required volume of antigen adsorbed onto Alhydro- 
gel at the optimal concentration was prepared, and left 
at room temperature for 30 minutes to ensure adequate 
flocculation. This was forced. from a syringe fitted 
with a fine gauge needle into an equal volume of sterile 
Bayol F (Esso Ltd., New Jersey, USA) containing 10% 
Arlacel A (Sigma Chemical Company, St. Louis, USA). The 
vaccine was emulsified in a tissue homogeniser. To check 
that the resultant emulsion was a water-in-oil emulsion, 
and not an oil-in-water emulsion, vaccine was dropped from 
a pipette onto water. If the drop remained discrete, the 
emulsion was of the desired type. Vaccines were kept at 
4°C until required. On occasion, the emulsion separated 




Bovine albumin vaccine 
In several experiments, it was necessary to use a 
placebo vaccine which did not contain any P. haemolytica 
antigen. This was made by adsorbing a solution of 0.1% 
bovine albumin (BA)(Bovine albumin (Fraction V) Miles 
Laboratories Ltd., Slough, England) onto Alhydrogel, at the 
optimal Aihydrogel concentration, and emulsifying this 
With an equal volume of sterile Bayol F containing 10% 
Arlacel A. 
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Techniques employed by collaborators 
Lymphocyte transformation responses to p.. haemolytica 
antigens 
Lymphocytes were obtained by layering a volume of 
heparinised (Heparin BP, Evans Medical, Liverpool, England) 
sheep blood onto an equal volume of a Ficoll (Pharmacia 
Fine Chemicals, Uppsala, Sweden)/Triosil (Tridsil 440 - 
Nyegaard & Co., Oslo, Norway) mixture (specific gravity 
1.075) and centrifuging the unmixed fluid at 500 g for 
30 minutes at room temperature. The lymphocytes, which 
formed a band at the Ficoll/Triosil-plasma interface, were 
removed and washed 3 times with Hank's Balanced Salt 
Solution (HBSS) containing 5 iu/ml of heparin before 
resuspension at 1x 10 
6 
cells / ml in RPMI 1640 medium 
(Gibco-Biocult, Paisley, Scotland) supplemented with 
5x 10 
5M 
2-mercaptoethanol and 20% autologous plasma. 
Twenty microlitres of a dilution of P, haemolytica type Al 
SSE was added to wells of sterile flat-bottomed microtitre 
plates, and 20 p1 of sterile medium added to wells used 
for non-stimulated control cultures. 200 pl of 
lymphocyte suspension was added to each well (ie. 2x 105 
cells/well). All cultures were set up in triplicate. 
Plates were incubated at 370 C in a moist atmosphere for 
5n 
5 days in a sealed box. Eighteen hours before termina- 
tion of the cultures, 1 PCi of m3thyl 
? 
H, Jthymidine 
(specific activity 5 Ci/mole) (Radio-Chemical Centre, 
Amersham, England) in 20 pl of RPMI medium was added to 
each well. At the end of the culture period, cells were 
adsorbed onto glass-fibre filter discs with a semi- 
automatic cell harvester (Cryotech, Abingdon, England). 
Dried discs were immersed in 1 ml scintillation fluid 
in vials and counted in an automatic liquid scintillation 
counter. Lymphocyte proliferative responses to 
P. haemolytica type Al were expressed as stimulation 
indices (S. I. ) 
Counts per minute due to incorporation of 
-3H-thymidine into lymphocyte culture 
containing R. haemolytica antigen 
S. I. _ 
Counts per minute due to incorporation of 3H-thymidine into unstimulated lymphocyte 
cultures 
Histological examination of mouse lungs 
Blocks were prepared from formol-fixed tissues, 
dehydrated in alcohols and embedded in paraffin wax. 
Sections were prepared and stained with haematoxylin and 
eosin (H. E. ). 
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IHA test for P. haemolytica antibodies in sheep sera 
Serum samples from sheep were tested for antibody 
against P. haemolytica by an IHA test (Shreeve, Biberstein 
and Thompson, 1972). 
Antigen was prepared from nutrient broth culture, 
incubated at 370C with agitation for 18 hours. The 
0 
culture was heated at 56C for 30 minutes. Bovine RBC, 
fixed in 1% gluteraldehyde, (Shirai, Dietel and Osterman, 
1975), were added to a final concentration of 0.5% And 
incubated at 37 
0C for 1 hour. The bovine RSC were then 
washed 3 times in buffered formalised saline (0.3% 
formalin), and resuspended at 5%. in the same solution. 
Doubling dilutions of test sera were made in buffered 
formalised saline in U-bottomed microtitration plates 
(Cookes Engineering Company, Alexandria, Virginia, USA). 
Equal volumes (0.025 ml) of sensitised bovine RBC were 
added to each well, the test was left at room temperature 








Challenge of SPF lambs with P13 virus and 
P. haemolytica 
This method of challenge infection consistently in- 
duced pneumonia in a high proportion of lambs and has 
been reported in detail elsewhere (Sharp, Gilmour, 
Thompson and Rushton, 1978). 
SPF lambs were delivered and maintained in isolation 
as described by Hart, Mackay, McVittie and Mellor (1971). 
Lambs were inoculated IT and IN with P13 virus (Wells, 
Sharp, Burrells, Rushton and Smith, 1976). Seven days 
after infection with P13 virus, the lambs were exposed to 
an aerosol of P. haemolytica (Gilmour, Thompson, Smitn 
and Angus, 1975). 
Lambs were examined clinically for 2 weeks after 
inoculation with P13 virus. To avoid any subjective 
influence, the clinician was unaware of the treatments 
given to each group of lambs prior to challenge, . and 
at the same time each day following the aerosol of 
P. haemolytica, a score for the degree of illness was 
awarded to each lamb. Dullness, pyrexia (> 40.60C) and 
abnormal respiration were assigned one point each, and 
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death four points. Lambs were killed if they showed 
signs of severe respiratory disease. 
Pathology and Bacteriology 
Lambs which died, or were killed when ill were 
examined at necropsy. Also, all surviving animals were 
killed 7-10 days after challenge with P. haemolytica and 
were submitted for post-mortem examination. Lesions on 
the dorsal and ventral aspects of the lung were recorded 
on lung diagrams, measured with a planimeter, and expressed 
as a percentage of the total lung surface area (Wells, 
Sharp, Rushton, Gilmour and Thompson, 1978). Lesion 
scorc- :: crc allocated on the basis of area affected, thus: - 
no lesions = 0, < 10% 5,11-25% = 10, >25% = 20. 
At the end of the experiment the daily clinical scores 
for each animal were added together. Statistical 
differences between the total scores (clinical and lesion 
scores) of the groups were determined by means of the 
Mann-Whitney test (Snedecor and Cochran, 1967). 
Portions of lung were. fixed in formol-saline and 
sectioned for histopathological examination. Further 
samples of lung tissue from lesions and "normal" lung 
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tissue were macerated with peptone water in a homogeniser 
(Colworth) and the number of viable P. haemolvtica counted 
by the method of Miles, Misra and Irwin (1938). 
Quantitative estimation of antibody to P. hae molytica 
in sheep sera by a micro-enzyme-linked immunosorbent 
assay (ELISA) 
The technique of this serological. test (Burrells, 
Wells and Dawson, 1979) was basically a microplate modifi- 
cation (Voller and Bidwell, 1975) of the ELISA technique 
of Engvall and Perlmann (1972). A 1/100 dilution of 
p. haemolytica type Al SSE in 0.05 M carbonate buffer, 
pH 9.6, was used to sensitise the wells of polystyrene 
microtitre plates (type M129A, Dynatech Laboratories Ltd., 
Billinghurst, Sussex). Individual wells were filled with 
300 pl of antigen solution, and the plates held at 4°C 
overnight. Plates were then washed 3 times with PBS 
containing 0.05% Tween 20 (PBS/Tween), shaking out excess 
fluid between each wash. Reference and test sera were 
not pretreated prior to testing and 1/1000 dilutions of 
these in PBS/Tween containing 0.02% sodium azide were 
added in 300 µl volumes to the wells of antigen-coated 
plates, and incubated at room temperature for 2 hours. 
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Serum dilutions were then aspirated from the wells, the 
plates washed 3 times with PBS/Tween, and 300 pl of 
alkaline phosphatase-conjugated anti-sheep IgC diluted 
1/1000 in PBS/Tween added. After incubation for 3 hours 
at room temperature, the wells were emptied and washed 
again with 3 changes of PBS/Tween. Enzyme substrate 
(p-nitrophenyl phosphate, Sigma Chemical Company, Poole, 
Dorset) at a concentration of 1 mg/ml in 10% diethanola- 
mine (B. D. H. Chemicals Ltd., Poole, Dorset) buffer, 
1*I 9.8, containing 0.5 mM magnesium chloride was added to 
the wells (300 µl/well). After 1 hour at room temperature, 
the reaction was stopped by the addition of 50 pl of 3.0 M 
sodium hydroxide. 
Absorbance of individual samples was. read at a wave- 
length of 400 nm in a colorimeter (Vitatron UPS Photometer) 
fitted with a micro flow-through cuvette. Results were 
recorded on a chart as peaks, the co-ordinates of which 
were translated into digital form on a punch-tape by means 
of an X-Y plotter. Five standard reference sera were 
included at the beginning of each test, and a further 
reference serum at the end of each run. The data tape 
was processed in a computer whose programme adjusted the 
values to allow for drift of the baseline during reading of 
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the samples, measured by variations in the results of the 
reference sera. The results were finally expressed in 
relation to a calibration curve provided by the standards. 
Chapter 1. - Experimental infection of mice with 57 
P. haemolytica 
Introduction 
The problems associated with establishing and 
evaluating experimental infection of mice with P. haemol- 
ytica have been discussed (see General Introduction). 
The work described in this chapter was aimed at the 
development of a method of challenge infection in mice 
with P. haemolytica, which could be used for investigation 
of the factors involved in immunity to P. haemolytica 
and screening of potential vaccines. Ideally, a model 
of P. haemolytica infection should have features similar 
to the field disease of pasteurellosis, with multiplication 
of the organisms within the host, resulting in a true 
infection. 
Two models of infection are described in this chapter. 
In the first, P. haemolytica was. given intranasally, and 
the second is a modification of the IP challenge method 
of Smith (1958). 
4 
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Materials and Methods 
Strain of P. haemolytica 
The strain of P. haemolytica used in these experi- 
ments is the P. haemolytica type Al strain described in 
General Materials and Methods. 
Intranasal challenge procedure 
Anaesthesia and IN inoculation of mice are detailed 
in General Materials and Methods. Each mouse received 
0.05 ml of P. haemolytica suspension IN. Control mice 
received 0.05 ml sterile PBS IN, 
prP ration of inocula for intranasa. ]. challenge 
Nutrient broth cultures were incubated at 37°C for 
5 hours, washed twice in PBS by centrifugation and 
resuspended in PBS to give an estimated concentration of 
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bacteria of between 10 -10 cfu/ml. This suspension 
comprised the inoculum for mice. 
Enumeration of viable P. haemolytica in lungs of infected 
mice 
At selected time intervals after challenge, infected 
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and control mice were killed by cervical dislocation and 
their lungs removed aseptically prior to maceration with 
9 ml sterile peptone water in a homogeniser (Colworth 
Stomacher, Seward Laboratory, London). Appropriate 
10-fold dilutions were made in peptone water, and viable 
counts performed by the method of Miles, Misra and Irwin 
(1938). in Experiments 1,. 3 and 4, a small sample of 
lung was removed from the diaphragmatic lobe for histol- 
ogical examination, before all the remainder was macerated 
for enumeration of bacteria. 
60 
Experiment 1- Intranasal infection of mice with 
varying numbers of P. haemolytica 
Design of experiment 
The challenge inoculum was prepared as described 
above. A series of 10-fold dilutions in PBS was made, 
and 7 groups each consisting of 6 C57 black mice, were 
infected IN with these dilutions. Table 1.1 shows the 
number of organisms received by each group. 
It has been shown that Swiss white mice challenged 
IN with P. haemolytica develop lesions in the lung which 
are maximal 3 days after challenge (Rushton, 1978). On 
the basis of this evidence, mice were killed on the third 
day. The lungs of these mice were removed and samples 
taken for histological examination (see General Materials 
and Methods). in this experiment, the lungs from each 
group of mice were assessed, and no attempt was made to 
score lungs individually. Each group was given a score 
(3+, 2+, 1+, , -) according to the extent and severity 
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The severity of the lesions observed in each group 
of mice 3 days after infection is shown in Table 1.1. 
The lesions have been described by Rushton (1978). 
Plate 1.2 shows the lung of a mouse which scored 1+ 
degree of pneumonia. When compared to the lung of a 
sham-inoculated mouse (Plate 1.1) it can be seen that 
the alveolar air spaces are reduced in size and partially 
collapsed, and that the interalveolar septa are swollen. 
In contrast, a severely affected lung which scored 3+, 
is shown in Plate 1.3. A large area of the lung is 
pneumonic, with focal consolidation and hyperplasia of 
the bronchiolar epithelium with focal sloughing. Some 
. of-the 
features of this pneumonia are illustrated at 
higher magnification in Plates 1.4 - 1.8. Plate 1.4 
shows detail from Plate 1.2, and illustrates swollen 
alveolar septa infiltrated by mononuclear cells, charac- 
teristic of lungs with 1+ severity of pneumonia. More 
severe pneumonia is seen in Plate 1.5, with focal consoli- 
dation, and an exudate of macrophages 'and neutrophils. 
The features of the most extreme pneumonia are shown in 
Plates 1.6 - 1.8, in which consolidation, bronchioles 
with hyperpl&stic epithelium, and a necrotic small artery 
are illustrated. " 
Plate 1.1 Lung from C57 black mouse given saline 
IN. Note expanded alveoli with thin 
septa. 
H. E. X76 
Plate 1.2 Lung from C57 black mouse given lÖ 
ý3 cfu 
P. haemolytica type Al IN (Experiment 
1)" 
The alveolar spaces are reduced in size. 
partly due to collapse, but also to 
swelling of interalveolar septa. 11his 
lung rates 1+ degree of severity- 
H. E. X76 
Plate 1.3 Lung showing 3+ degree of severity. 
The main changes are pneumonia with 
focal consolidation, and hyperplasia Of 
bronchiolar epithelium with focal 
sloughing (arrows). 




Plate 1.4 Higher magnification of section illu- 
strated in Plate 1.2, showing swollen 
interalveolar septa infiltrated by. 
mononuclear cells. Some hypertrophied 
lining cells, possible type II alveolar 
cells, are also present (arrows) 
H. E. X875 
Plate 1.5 Pneumonia associated with 106.8 cfu 
P. haemolytica type Al given IN (Experi- 
ment 3). There is focal consolidation, 
with an exudate of macrophages and neutro- 
phils 
H. E. X875 

Plate 1.6 Severe consolidation with cellular 
'exudate. A respiratory bronchiole 
(left) has a hyperplastic lining in 
the process of sloughing 
H. E. X87'5 
Plate 1.7 Bronchiole with hyperplastic epithelium 
H. E. X875' 
Plate 1.8 Necrosis of small artery within an area 
of consolidation. A narrow perivascular 
lymphoid cuff has formed, and the wall 
of the artery is infiltrated by mono- 
:. uclear cells 
H. E. X875 
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Tt is evident from Table 1.1 that the severity of 
the lesions observed was greatest in the lungs of mice 
infected 
with the largest numbers of organisms. 
Inoculation of fewer than 104.3 cfu P. haemolytica 
type Al did not produce lesions. 
No bacteria were observed in the lungs of Mice 
3 days after infection. This suggested that perhaps 
they had been cleared from the lung by this time, and 
Experiment 2 was designed to investigate this possibility. 
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Experiment 2- Viable counts of P. haemolytica in the 
lungs of mice after infection 
It was important to know whether bacteria were 
cleared from the lung after challenge, of if they multip- 
lied to establish a true infection. This experiment was 
designed to discover which of these two alternatives 
occurred. 
Design of experiment 
Fifty mice were each inoculated IN with 107 cfu 
F. haemolytica type Al, as described previously. Groups 
of 10 mice were killed at the time of challenge and 4 hours, 
8 hours, 12 hours and 16 hours after challenge. Viable 
counts were performed on the lungs of individual mice. 
In the second part of this experiment, 50 mice were infec- 
ted with 107 cfu P. haemolytica type Al and killed in 
groups of 10 at the time of challenge and 4 hours, 24 hours, 
48 hours and 72 hours later. Viable counts were performed 
on the lungs. 
Viable counts were expressed as log10, and the mean 
and standard error (SE) calculated for each group. 
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Results 
The results are depicted graphically in Fig. 1.1. 
It appears that no multiplication of P. haemolytica 
type Al occurs in the lungs of infected mice, but that 
the organisms are removed or killed in situ and 48 hours 
after challenge the lungs are substantially free from 
P. haemolytica. From this data it is impossible to 
tell whether the bacteria are killed within the lung, or 
if they are transported from the lung. Lesions are 
present within the lungs 3 days after infection, yet no 
viable bacteria are present in the lungs at this time 
(not shown in Fig. 1.1). 
Figure 1.1 Viable counts of P. haemolytica type Al 
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Ex eriment 3- Comparison of ha lo thane and thiopentone 
sodium as anaesthetics for intranasal infection 
Experiment 3 was performed to discover if the 
anaesthetic given by inhalation was. responsible for the 
lesions. 
Mice are exposed to halothane by inhalation, and 
it is conceivable that this anaesthetic may be partly or 
wholly responsible for the lesions seen in the lungs 
3 days after infection. To eliminate this possibility, 
mice were anaesthetised with either halothane, or 
thiopentone sodium given IP, before IN infection with 
p., haemolyti. ca type Al. 
Desicn of experiment 
Twenty-eight mice were randomly allocated to two 
groups of 9 mice and two groups of 5 mice each 
(Table 1.2). 
The 9 mice in Group 1 were anaesthetised with 
halothane, 
and infected IN with 106.8 cfu P. haemolytica type Al as 
described previously. The 9 mice 
in Group 2 were 
anaesthetised by IP injection of 0.2 ml of 10% thiopentone 
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Essex), and infected IN with 10 
6.8 
cfu P. haemolytica 
type Al. Groups 3 and 4 each consisted of 5 mice, 
which were anaesthetised with halothane and thiopentone 
sodium respectively, prior to inoculation with 0.05 ml 
sterile PBS. 
Three days after infection, all mice were killed, 
and samples removed from their lungs for histological 
examination. Lungs from individual mice were assessed 
in this experiment, and awarded a score to represent the 
extent and severity of lesions. Mice scoring 3+ were 
awarded 3 points, those scoring 2+ were awarded 2 points, 
those scoring 1+, 1 point, and mice scoring 
+ 
were given 
0.5. The total for each group was calculated, to enable 
comparisons to be made between the different groups. 
Results 
The results of Experiment 3 are shown in Table 1.2. 
The challenge inoculum in this experiment was slightly 
6.8 
lower than usual (10 cfu P. haemolytica type Al per 
mouse), and probably as a result of this, three mice in 
both Group 1 and Group 2 showed no lesionsain their lungs. 
Lesions in griups 1 and 2 varied from very severe (3+) to 
negative (ý), and the spread was similar in the two groups. 
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Control mice given sterile PBS IN showed no lesions. 
It can be concluded from this experiment that halo- 
thane is not responsible for the lesions 3 days after 
challenge, since mice given the same challenge, but 
anaesthetised with thiopentone sodium (Group 2), had 
similar lesions to mice in Group 1, and the mice in 
Group 3, which were anaesthetised with halothane, but 
not infected, displayed no lesions. 
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Experiment 4- Comparison of IN infection with live and 
heat-killed P. haemolytica 
No detectable bacteria are present in the mouse lung 
when the lung lesions are present, and Experiment 3 
demonstrated that the lesions were not a direct result 
of anaesthesia. These two observations led to the 
suggestion that the lesions may be the result of the 
presence of large amounts of bacterial material, in the 
lung, and that dead P. haemolytica may produce similar 
results. Experiment 4 was designed to test this hypo- 
thesis. 
Desi n of experiment 
An inoculum of P. haemolytica type Ai was prepared 
as described previously. One half was heat-inactivated 
at 600C for 30 minutes. Two dilutions (10-1 and 10-2) 
of both live and heat-killed inocula were made, and 
viable counts performed to determine the number of 
organisms present, and to check the sterility of the heat- 
killed preparation. 
Forty-two mice were randomly allocated to 7 groups 
of 6 mice each. Mice were anaesthetised with halothane, 
6 
and inoculated IN with either live or heat-killed 
P. haemolytica at undiluted, 10-1 or 10 
2 
dilutions. 
The seventh group was inoculated with sterile PBS. 
The treatments given to each group are detailed in 
Table 1.3. 
Three days after challenge, the mice were killed and 
samples of lung examined histologically. Scores were 
awarded as in Experiment 3. 
Results 
The results are shown in Table 1.3. The largest 
live inoculum was that given to mice of Group 6 (10'2 cfu 
6 
p. haemolytica type Al/mouse), and lesions of varying 
severity were observed in five of the six mice in this 
group. Mice in Group 3 were given equivalent numbers of 
heat-killed bacteria and lesions were also present in 
five of the six mice. The remaining mice in these two 
groups showed no convincing lesions. Smaller inocula, 
either live or dead, produced few positive results. The 
control mice (Group 7), -which were given sterile PBS, 
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It can be concluded from this experiment that 
similar lesions can be produced in the lungs of mice 
3 days after IN challenge with an inoculum of 10 
6'2 
cfu 
of either live or heat-killed P. haemolytica type Al, and 
that these lesions are not the result of ongoing infection, 
but are probably due merely to the presence of bacterial 
material in the lung. 
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Experiment 5- Intraperitoneal challenge procedure; 
preparation of inocula for IP challenge of mice and 
determination of LD50 
Design of experiment 
A 300 ml volume of NB was inoculated from a fresh 
blood agar culture of P. haemolytica type Al. The broth was 
incubated for 10 hours at 37°C, and the bacteria obtained 
by centrifugation at 1000 g for 20 minutes at 40C. The 
bacteria were washed twice in 0.15 M saline, and resus- 
pended in 10 ml saline. A series of 10-fold dilutions 
was made in saline from this suspension, and a viable 
count performed. The undiluted suspension and dilutions 
10 
1-10 5 
were incorporated into a 5% suspension of hog 
gastric mucin, pH 7.2 (ICN Pharmaceuticals Inc., Life 
Sciences Group, Plainview, NY), at a ratio of 1 part 
bacteria to 4 parts gastric mucin. Groups of 5 mice 
were inoculated IP with 0.5 ml of each dilution and the 
number of deaths recorded 48 hours later. Generally, 
no further deaths occurred after this time. The LD50 
was calculated by the method of Reed and Muench (1938). 
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Results 
The LD50 of this strain of P. haemolytica type Al 
was 105.3 cfu when given IP in gastric mucin to mice. 
In subsequent experiments with this method of challenge, 
the inoculum was always greater by at least 10 
0'5 
cfu 
than the LD50' 
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Experiment 6- Growth of P. haemolytica type Al in the 
livers and spleens of normal mice 
This experiment was designed to determine if the 
organisms multiplied within the mouse and established 
a true infection. 
Design of experiment 
An inoculum of P, haemolytica type Al was prepared 
as described in the preceding experiment. A group of 
20 mice was inoculated IP with 107.1 cfu P. haemolytica 
type Al in gastric mucin. At time intervals of 1,2,3 
and 8 hours after challenge groups of 5 mice were killed 
by cervical dislocation, and their livers and spleens 
removed aseptically. These organs were indivually 
macerated with 9 ml peptone water in a homogeniser and 
serial 10-fold dilutions in peptone water plated out for 
viable counting. The mean counts 
± SE for each group 
were calculated and expressed as log10 cfu. 
Results 
The viable counts of P. haemolytica type Al in the 
livers and spleens of mice are shown in Fig. 1.2. Each 
Figure 1.2 Viable counts of P. haemolytica type Al 
in the livers and spleens of mice foll- 
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point plots the mean 
± SE of the counts for 5 livers or 
spleens, expressed at log10 cfu. Counts from individual 
livers and spleens are given in Appendix 1. From 2 hours 
after infection, the organisms multiplied in both organs, 
with similar growth rates in each. This showed that 
"true" infection was taking place, with multiplication of 
the organisms within the host. 
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Experiment 7- Vaccination of mice by IP and SC routes 
prior to challenge with P. haemolytica type Al 
This experiment was designed to determine if the 
model of Ii` infection with P. haemolytica could be used 
to demonstrate protection afforded by vaccination with an 
experimental P haemolytica vaccine, and to ascertain the 
most suitable route for vaccination. 
Design of experiment 
Fifty mice were randomly allocated to 5 groups of 
10 mice each. Mice in Group 1 were unvaccinated controls. 
Those in Group 2 were inoculated SC with 0.1 ml of 
P. haemolytica type Al SSE adsorbed onto Alhydrogel 
and emulsified in mineral oil, and mice in Group 4 were 
inoculated with 0.1 ml of this vaccine IP. Mice in 
Group 3 and Group 5 were given 0.1 ml of BA adsorbed 
onto Alhydrogel and emulsified in mineral oil, by the Sc 
and IP routes respectively. Details of these vaccine 
preparations are given in General Materials and Methods. 
Three weeks after vaccination, inocula of P. haemoly- 
tica type Al in gastric mucin were prepared as described 
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for previous IP challenges. Five of the mice in each 
group were challenged IP with 108 
6 
cfu and the remaining 
5 with 10 
7'6 
cfu. The number of deaths was recorded 
48 hours later. 
Results 
Deaths 48 hours after challenge are shown in Table 1.4. 
All 10 control mice died. Mice vaccinated SC with 
P. haemolytica vaccine were protected from challenge with 
107.6 cfu, but four of the five mice challenged with 
108.6 cfu died. Two of the five mice in Group 3 
(vaccinated SC with BA vaccine) survived challenge with the 
smaller number of organisms, but all those given the higher 
challenge died. 
In contrast, mice in Group 4 (vaccinated with 
P. haemolytica vaccine IP) survived both challenge doses, 
and mice in Group 5 (vaccinated IP with BA vaccine) all 
survived the lower challenge and four of the five mice 
8' 
challenged with lo6 cfu, survived. 
IP inoculation of the P. haemolytica vaccine afforded 
complete protection from both challenge doses, whereas only 
Table 1.4 
The effect 'of vaccination by IP and SC routes upon IP 
challenge with P. haemolytica type Al 
Number of deaths 48 
Route of hours after challenge 
Group adminis- in groups of five mice 
No Vaccine tration "108'6 cfu 107.6 cfu 
1 - - 5 5 
2 P. haemolytica* Sc 4 0 
3 BA* Sc 5 3 
4 P.. haemolytica IP 0 0 
5 BA IP 1 0 
* Both antigens adsorbed onto aluminium hydroxide and 
emulsified in mineral oil. 
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one mouse vaccinated SC with the P. haemolytica vaccine 
survived. However, the adminstration of the BA vaccine 
IP was shown to have a protective effect comparable to IF 
vaccination with the P. haemolytica vaccine. It is 
reasonable to conclude that the protection demonstrated 
with IP administration of the P. haemolytica vaccine is, 
at least in part, due to some non-specific reaction in 
the peritoneum. For this reason, the SC route of 
vaccination was chosen in preference to the IP route in 
subsequent experiments. 
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Experiment 8- The effect of vaccination of mice with 
P. haemolytica type Al vaccine upon the growth of 
organisms in the liver following IP challenge with 
P. haemolytica type Al 3 weeks later 
Design of experiment 
Twenty-five mice were each inoculated SC with 0.1 ml 
p. haemolytica type Al vaccine. Three weeks later, these 
mice and a group of 25 uninoculated controls were challen- 
ged IP with 10 
6.6 
cfu P. haemolytica type Al in gastric 
mucin. Five vaccinated and 5 control mice were killed 
at the time of challenge, and 2,4, and 6 hours thereafter. 
Their livers were removed aseptically, and viable counts 
-determined. 
Results 
Viable counts of P. haemolytica type Al in the livers 
of vaccinated and control mice are shown in Fig. 1.3. 
Each point represents the mean 
1 SE of counts from 5 mice, 
expressed as log10 cfu. Counts from individual livers 
are given in Appendix 1. Viable counts increased 
exponentially in the livers of untreated mice, whereas 
there was a reduction in the number of viable bacteria 
in the livers of vaccinated mice. Five control mice 
Figure 1.3 Viable counts of P. haemolytica type Al 
in the livers of control and vaccinated 
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. which were not sacrificed all 
died with 19 hours. In 
contrast, 5 infected vaccinates appeared healthy at that 




The purpose of the work described in this chapter 
was the development of a method of P. haemolytica 
challenge in mice which would be suitable for the study 
of experimental vaccine preparations. 
At first, the model of IN infection seemed promising. 
Lesions developed in the lung, the organ primarily involved 
in pneumonic pasteurellosis, and these were not caused by 
the anaesthetic used during challenge, so were probably 
the result of an effect of the bacteria. However, there 
was no net multiplication of P. haemolytica in Lb e lung, 
which was cleared by n8 hours a. ftcr infection. ruzhton 
(1978) recovered P. haemolytica in varying numbers from 
the lungs of some mice 3 days after challenge with 
P. haemolytica by this method. In that study, viable 
counts were performed upon pools of lungs from 5-10 mice, 
and not from individual mice, as in this experiment. It 
is not evident from these results whether P. haemolytica 
multiplies within the lung and is removed from it at a 
faster rate, or whether the bacteria are cleared without 
any multiplication. Bacteria may be killed within the 
lung, or removed from it. The former possibility is 
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the more likely. Green and Kass (1964) showed that 
when mice were exposed to an aerosol of radio-labelled 
Staphylococcus aureus or Proteus mirabilis, and the rate 
of disappearance of viable bacteria compared with the rate 
of their mechanical removal, bacterial viability declined 
by 80-90% in 4 hours, whereas radioactivity declined by 
only 14-20%. The disparity between these rates indicated 
that mechanical removal comprised a relatively small 
fraction of the total clearing process. The decline 
in viability of P. haemolytica in the mouse lung is not 
as rapid, but it is probable that methods of removal are 
similar. 
The fact that P. haemolytica does not multiply in 
the mouse lung is a serious disadvantage, but more important 
is the fact that the bacteria do not have to be living to 
cause lung lesions. The lesions therefore are not 
necessarily related solely to infection with viable 
P. haemolytica. Rushton (1978) claimed of this model 
that "the mouse pneumonia, besides being quickly, easily 
and cheaply induced, provides an opportunity for studying 
P. haemolytica in the lung without the development of 
extensive ch_nges and subsequent death". Despite these 
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obvious advantages of low cost, and rapidity of induction 
of lesions, it was considered that the experiments 
described in this study showed that the lesions were 
due to a toxic effect of the bacteria, and that the model 
was therefore unsuitable for the study of P. haemolytica 
infection, particularly the study of immunity. Attention 
was turned to the model of infection of mice with 
P. haemolytica by the IP route, which was developed by 
Smith (1958). 
In this model, P. haemolytica multiplies within the 
host and causes death within 48 hours. In his original 
work, Smith (1958) recorded death or survival of mice, 
and did not quantify the number of organisms present. 
However significant the differences between death or 
survival may be, data of this kind reveal nothing of the 
machanism of bacterial inactivation by the host. Obviou- 
sly, the survival of 100% of a group of vaccinated mice, 
in the face of 100% mortality in controls, represents a 
convincing demonstration of protection, but the interpre- 
tation of, for example, 50% survival of vaccinated mice, 
or increased time to death, is more difficult. This 
becomes an even greater problem if the virulence of the 
infecting agent has been enhanced by some form of immuno- 
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suppresion of the host. 
Serial enumeration of the populations of bacteria 
in both vaccinated and control mice circumvents some of 
these criticisms. The criterion used to estimate the 
efficacy of vaccines is a significant shift in the bacterial 
growth rate, which may be sufficient to prevent disease. 
Such studies are complementary to mortality/survival data. 
Detailed growth curves obtained using both actively 
and passively immunised animals have revealed the nature 
of the immune response to a number of microbial parasites, 
including Salmonella species (Collins, 1974). Extensive 
studies of a similar nature have been performed with 
P. inultocida infection of mice (Woolcock and Collins, 
1976). Two injections of heat-killed vaccine, incorpor- 
ated in CFA, protected absolutely against parenteral 
challenge with P. multocida, and growth of P. multocida 
in the livers and spleens of vaccinated mice was 100-fold 
lower than in controls. Hyperimmune mouse serum, 
administered IP prior to SC challenge, was shown to be 
highly protective. In view of these experiments, 
enumeration of viable P. haemolytica in challenged mice 
was considered to be of greater value than mortality/ 
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survival data alone. 
An aim of the present study was development of a 
model which could be used for screening potential vaccine 
preparations. By 5-6 hours after infection, viable 
P. haemolytica in the livers of control mice had increased 
by at least 10-fold, and those in the livers of success- 
fully vaccinated mice had decreased sufficiently for 
differences between the two groups to be convincingly 
demonstrated. In subsequent experiments, it was 
considered sufficient to kill mice from each group only 
at the time of challenge, and at one time interval there- 
after. This meant that fewer mice would be required to 
screen each vaccine preparation, an advantage for investi- 
gation of vaccine preparations on a large scale. The 
determination of LD50 values for each vaccine would require 
far greater numbers of animals. 
The P. haemolytica and BA vaccines administered IP 
gave similar degrees of protection (Experiment 7). Non- 
specific stimulation of peritoneal macrophages can occur 
following the introduction of a variety of substances, 
such as serum and mineral oil, *into the peritoneum (Stuart, 
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Habeshaw and Davidson, 1978). It is possible that such 
stimulation took place in these experiments and for that 
reason, the IP route of vaccination was avoided in later 
experiments. It is interesting to note that Smith (1959A) 
demonstrated a non-specific protective effect if diluted 
mouse serum, saline or veronal-saline buffer were inocu- 
lated IF, 5-6 hours prior to challenge with P, haemolytica 
in gastric mucin. This effect was evident only at lower 
challenge doses of P. haemolytica, when fewer deaths 
occurred in treated mice- than in controls. 
Smith (1959A) demonstrated protection of mice from 
IP challenge with P. haemolytica by IP inoculation of living 
P. ' haemolytica or a formol-saline P. haemolytica vaccine. 
Protection afforded by IP vaccination with either of 
these preparations was superior to that given by a single 
SC vaccination with the formol-saline vaccine flocculated 
by sodium bicarbonate and potassium aluminium sulphate, 
then emulsified in mineral oil. Although the strain of 
P. haemolytica used in these experiments was isolated from 
a case of lamb septicaemia, and the strain used in the 
present study was from a case of sheep pneumonia, these 
results are in agreement. Smith (1959A) also found that 
IV administration of the formol-saline vaccine gave a 
R7 
similar degree of protection to that achieved when it 
was given IP. The vaccine used in the present study 
was an oil emulsion, and unsuitaLle for IV inoculation. 
The major disadvantages of the SC immunisation and 
IP challenge of mice model is that it bears no resemblance 
to the field disease of pneumonic pasteurellosis in sheep, 
and that the mouse is not a natural host of P. haemolytica, 
necessitating the use of gastric mucin to enhance its 
virulence. The model of pneumonic pasteurellosis in 
sheep (Sharp, Gilmour, Thompson and Rushton, 1978) also 
has the disadvantage that the host must be comprimised, 
in this case by P13 virus infection, before infection 
with P. haemolytica can be established. However, the 
lesions produced in lambs by this method do resemble those 
of the field disease. The P. haemolytica type Al vaccine 
used in this study has also been shown to protect SPF 
lambs against challenge with P. haemolytica type Al 
superimposed on P13 virus infection (Gilmour, Martin, 
Sharp, Thompson and Wells, 1979; Chapter 2 of this thesis), 
which suggests that there may be some correlation between 
results obtained in the two challenge systems. This 
model of P. haernolytica infection in mice has in its 
favour that an infection can be established, and its 
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progress followed in the face of various vaccination 
procedures. Further experiments using this model are 
described in later chapters. 
Chapter 2 89 
Me. ̂ hanisms of immunity to P. haemolytica in sheep 
Introduction 
Assessment of the efficacy of P. haemolytica vaccines 
has previously been based upon serological criteria. The 
IRA test has been widely used for the detection of 
antibodies to P. haemolytica in sera from vaccinated 
lambs (Cameron. and Smit, 1970). There is a lack of 
evidence to suggest that measurement of serum antibody 
titres to P. haemolytica gives any indication of the 
ability of vaccines to prevent disease. Correlation has 
been demonstrated between serum IHA titres of lambs 
vaccinated against P. haemoivtica type Al and the 
protective capacity of these sera given passively to 
mice (Gilmour, personal communication). ' The resistance 
of individual lambs to challenge with P. haemolytica type 
Al did not correlate with either of these parameters. 
Consequently, the role of humoral immunity in protection 
against P. haemolytica is not clear. 
Sterility of the lungs is normally maintained by the 
combined antibacterial activity of the mucociliary, 
phagocytic and immune systems. Inhaled bacteria which 
impact in the upper regions of the respiratory airways 
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are physically removed by the mucociliary transport 
systems (Kilburn, 1967; Green, 1968), and bacteria 
invading the lung are intercepte3 minutes after their 
entry by alveolar macrophages (AM) (Goldstein, Lippert 
and Warshauer, 1974). The sequer. ýe of events involved 
in bacterial inactivation in the lung has been extensively 
studied in mice, rats and guinea pigs (Goldstein, Green 
and Seamans, 1970; Goldstein, Lippert and Warshauer, 
1974; Green and Kass, 1964; Jakab and Green 1973A and 
1973B). Little is known about the local defence mechan- 
isms which operate in the sheep lung during pasteurellosis. 
Two experiments are described in this chapter. The 
first was an investigation into' phagocytosis of P. haemol- 
ytica by sheep lung wash cells in vitro, in the presence 
and absence of serum from immunised lambs. In the second 
experiment, lambs were passively immunised with hyperimmune 
serum prior to challenge with P. haemolytica. These two 
experiments were performed in the hope that some insight 
would be gained into the mechanisms which may be important 
in immunity to P. haemolytica in sheep. 
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Materials and Methods 
Lambs 
All lambs were hysterectomy-derived, colostrum- 
deprived, and were reared under SPF conditions (Hart, 
Mackay, McVittie and Mellor, 1971). 
Vaccine 
The vaccine used throughout was P. haemolytica type 
Al SSE, adsorbed onto Alhydrogel and emulsified in mineral 
oil, as described in General Materials and Methods. 
Bacteria 
P. haemolytica type Al as described in General 
Materials and Methods was used in both experiments. 
Preparation of antiserum pool for Experiment 2 
The pool of antiserum to P. haemolytica type Al used 
in Experiment 2 was prepared from blood collected from 4 
colostrum-deprived lambs. These lambs were reared for 
the first two weeks of life under gnotobiotic conditions, 
then transferred to a room which had been thoroughly 
cleaned and . isinfected. The lambs had no direct or 
ý2 
indirect contact with conventional animals and were thus 
protected from acquiring unintezc. ional P. haemolytica 
infection. P. haemolytica type Al vaccine was injected 
intramuscularily on 3 occasions, the 2nd and 3rd injections 
being given 1 month and 2 months r. --spectively after the 
first. Blood samples were taken at weekly intervals, 
and the serum titre of IRA antibody to P. haemolytica 
type Al determined. On the basis of these results blood 
for preparation of the serum pool was collected in the 
2 weeks prior to and the 4 weeks after the final injection 
of the vaccine. After separation from the clot, *the 
serum was clarified by filtration and sterilised by passing 
it-through a 22 pm membrane filter. The antiserum pool 
had an lHA titre to P. haemolytica type Al of 1024, and 
lacked antibodies to P13 virus, as detectable by haemagglu- 
tination inhibition assay as adapted to microtitre plates 
(Smith, 1975). 
A negative control pool of serum obtained from 4 to 
6 week old SPF lambs was prepared in a similar manner. 
No antibodies to P. haemo1ytica type Al or P13 were detec- 
ted in this serum pool. 
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Experiment 1- Growth of P. haemolytica in vitro in the 
presence of lung wash cells and serum 
The aim of this experiment was to demonstrate 
phagocytosis of P. haemolytica by lung wash cells from 
SPF lambs in vitro, and to determ. ne the effect of 
vaccination upon this parameter. 
Design of experiment 
Eight SPF lambs were allocated to 2 groups of 4 lambs 
each. Lambs in Group 1 were vaccinated SC in the brisket 
with 2 ml P. haemolytica type Al vaccine at 3 weeks of age. 
Lambs in Group 2 were untreated. 
Serum samples were collected from all 8 lambs at the 
time of vaccination and at intervals of 1,2,3, and 5 
weeks post-vaccination. An additional sample was taken 
prior to slaughter. Antibodies of IgG class to 
p. haemol ty ica in these samples were measured by means of 
the ELISA technique as detailed in General Materials and 
Methods. 
Seven to nine weeks after vaccination, lambs were 
killed in pairs (1 vaccinate and 1 control) by IV injection 
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of 5 ml pentabarbitone sodium (Euthatal (200 mg/ml); 
May & Baker Ltd., Dagenham, England). The chest was 
opened and the trachea clamped before removal of the 
lungs to avoid contamination of the lungs by blood. Lungs 
were lavaged by pouring sterile HBZS containing 0.1% 
gelatin (gelatin-Hanks) into the trachea, now with the 
clamp removed, through a sterile filter funnel covered 
with gauze. The lungs were kneaded gently, and the 
fluid tipped out into sterile centrifuge jars. The cells 
were sedimented by centrifugation at 200 g for 20 minutes 
at 40 C. The supernate was removed, and the cells washed 
twice more in gelatin-Hanks. The cells were counted in 
an Improved Neubauer Haemocytometer, and viability estimated 
by exclusion of trypan blue from the cytoplasm. The 
majority of the cells had morphology of AM, although other 
cell types, such as lymphocytes were present. Culture 
mixtures were set up in sterile plastic tissue-culture 
grade tubes with screw caps (Sterilin Ltd., Teddington, 
Middlesex, England) as detailed in Table 2.1. The total 
volume of each culture was 2.5 ml, and each was set up in 
triplicate. To each tube was added 10 pl of P. haemolytica 
5' 




This inoculum was prepared from a 50 ml NB culture, incubated 
for 6 hours at 37°C with agitation. The bacteria were 
Table 2.1 
Composition of cultures in Experiment 1 
Source of Source of lung wash cells 
Culture Serum (16%) (105.3/ml) 
A V V 
8 C V 
C V - 
D C C 
E V C 




washed twice in saline by centrifugation and resuspended 
in saline at an estimated concentration of 107-108 cfu/ml. 
These experiments were performed on the same day as the 
lambs were killed. 
Cultures were incubated at 37°C with rotation. At 
the start of the experiment, and 30,60 and 120 minutes 
later, 0.5 ml aliquots were removed and added to 1.5 ml 
ice-cold gelatin-Hanks, to stop any reaction, and 
centrifuged at 110 g for 4 minutes. Preliminary 
experiments showed that this centrifugation sedimented 
the lung wash cells, but did not alter the viable 
count of bacteria in the supernate. Ten-fold dilutions 
of the supernate were made, and viable counts performed 
by the method of Miles, Misra and Irwin (1938). 
Results 
Antibody to P. haemolytica"as measured by the ELISA tech- 
ni ue 
The sera of the lambs in Group 2 (unvaccinated) were 
negative for P. haemolytica antibodies, as measured by 
this test, for the duration of the experiment. The titres 
of the vaccinated lambs are shown in Fig. 2.1. Specific 
Figure 2.1 Titres of IgG antibodies to 
P. haemolytica type Al in sera of 
vaccinated lambs, measured by the 
ELISA technique 
0 Lamb No 10 
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C-- ----10 Lamb No 22 
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circulating IgG was detected as early as 2 weeks post- 
vaccination (lamb 14 - 1/104, lamb 32 - 1/471 The titres 
in all 4 lambs increased by varying degrees up to week 5, 
and rose sharply thereafter. 
Growth of P. haemolytica in vitro in the presence of 
lung wash cells and serum 
Viable counts in the supernates of cultures were 
converted to log10, and means calculated for each culture. 
An analysis of variance was performed on the results, 
which are depicted graphically in Figs. 2.2-2.5. 
The cultures in which serum from control 1enbs was 
included (Cultures A, C and E) supported the growth of 
P. haemolytlea in the supernate, and over the 2 hours of 
the experiment the numbers of organisms increased by 
1.5 
approximately 10 cfu/nil. In cultures which contained 
serum from vaccinated lambs . 
(Cultures B, D and F), the 
increase in numbers of P. haemolytica. in the supernate 
was less than 10-fold. The difference between these 2 
groups was highly significant. (P<0.001). This effect 
of serum was the same regardless of whether the lung wash 
cells in the system were from vaccinated or control lambs, 
Figure 2.2 Viable counts of P. haemolytica type Al 
in the supernates of cultures A and B 
at various time intervals after infec- 
tion. SED = 0.150 
0--0 culture B 
ý----ý culture A 
Figure 2.3 Viable counts of P. haemolytica. type Al 
in the supernates of cultures D and E 
at various time intervals after infec- 
tion. SED = 0.150 
4 
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Figure 2.4 Viable counts of P. haemolytica type Al 
in the supernates of cultures C and F 
at various time intervals after infec- 
tion. SED = 0.150 
a-------0 culture F 
----ý culture C 
Figure 2-. 5 Mean viable counts of P. haemolytica 
type Al in theAsupernates of cultures 
containing serum from vaccinates 
(cultures A, C and E) and cultures 
containing serum from controls (cultures 
B, D and F) at various time intervals 
after infection. SED = 0.087 
'%---ti cultures B, D and F 








30 60 90 120 














30 60 90 120 
Minutes after start of experiment 
96b 
or indeed if there were no lung wash cells present 
(Cultures C and F). This is illustrated in Fig. 2.5, in 
which the means at each time interval have been plotted 
for all cultures containing serum from vaccinates 
(Cultures A, C and E) and all those containing serum 
from controls (Cultures B, D and F). The curves in this 
graph are similar to'those in Figs. 2.2-2.4, which 
illustrate the curves from each combination of cells and 
sera, No. phagocytosed bacteria could be seen within 
lung wash cells, which had been exposed to P. haemolytica 
type Al, smeared onto a slide, and stained with Giemsa. 
It can be concluded from this experiment that 7-9 
weeks after vaccination, sera from lambs vaccinated against 
P. haemolytica have a bacteriostatic effect upon the growth 
of P. haemolytica. The presence of lung wash cells, whether 
from vaccinated or control lambs, had no influence upon 
this effect. it is debatable as to whether phagocytosis 
of P. haemolvtica in these cultures occurred, but if it 
did, the level was too low to detect in- this system. 
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Experiment 2- The roles of antibody and cell-mediated 
immunity (CMI) in combined infection of SPF lambs with 
P13 virus and P. haemolytica type Al 
Many aspects of this experiment were carried out by 
collaborators at the Moredun Research Institute and the 
principal role of the author was in experimental design 
and interpretation of the results. The lymphocyte 
transformation tests were performed by Mr. C. Burrells, 
clinical examinations of lambs by Dr. J. M. Sharp, 
and pathology by Dr. B. Rushton. The serology was 
carried out by Mr. D. A. Thompson. The method of 
challenge of S PF lambs with P. haemoiytica, superimposed 
upon P13 virus infection is described in detail in 
"General Materials and Methods - Techniques employed 
by collaborators". 
Design of experiment 
Twenty-seven hysterectomy-derived, colostrum-deprived 
lambs were reared under SPF conditions. These lambs were 
allocated to 2 groups of 8 lambs, a third group of 7 lambs, 
and a fourth group of 4 lambs. The treatments given to 
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age, the 8 lambs in Group 1 were vaccinated SC with 2 ml 
p. haemolytica type Al vaccine over the sternum. Lambs 
in Groups 2 and 3 were not treated at this time. Three 
weeks later, the lambs in Groups 1,2, and 3 were challen- 
ged intrabronchially and intratracheally with 10 
7'5 
TCID50 P13 virus (see General Materials and Methods). 
Six days after infection with P13 virus, the lambs in 
Group 2 each received 200 ml of the antiserum to 
p. haemolytica type Al raised in colostrum-deprived lambs, 
and the lambs in Group 3 received 200 ml of the control 
serum. The serum was administered by IP injection in 
2 doses of 100 ml, and the second dose given 6 hours 
after the first. Eighteen hours after the second 
injection, the lambs in Groups 1,2 and 3 were exposed 
In groups of 4 for 15 minutes to an aerosol of P. haemoly- 
tica type Al produced by a Wrights nebuliser (103.0 cfu 
per litre of air). Lambs in Group 4 were neither 
vaccinated, nor infected with either P13 virus or 
p, haemol_ytica, and served as controls. 
Blood samples were taken from 4 lambs in each group 
prior to vaccination, and thereafter at intervals during 
the 4 week period until exposure to P. haemolytica; 
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lymphocyte cultures were set up from these bloods to 
determine specific proliferative responses in the presence 
of P. haemolytica type Al antigen (see General Materials 
and Methods). Further cultures were also prepared from 
the same lambs immediately prior to infection with 
P. haemolytica type Al, 3 days and 5 days after infection. 
The lambs in Group 4, which were not infected, were sampled 
on these latter 3 occasions. 
Serum samples were collected from lambs at weekly 
intervals throughout the experiment, and additional 
samples were taken prior to challenge. These were tested 
for antibody to P. haemolytica by the IHA test (see General 
Materials and Methods). 
Results 
Serology 
Lambs vaccinated with the P. haemolytica vaccine 
responded by production of antibodies detected by the IHA 
test (Table 2.3). Maximum titres (geometric mean = 45.2) 
were observed on the day that lambs were challenged by 
exposure to aerosol of P. haemolytica. 
4 
Table 2.3 
IRA titres of sera from lambs in Experiment 2 
Group Lamb No IHA titre in sera at age 
14d 21d 28d 35d 41d 42d 
9 - 8 32 64 ND 128 
13 - 4* 8 16 ND 64 
17 - 8 4 32 ND 128 
18 - 4 4 8 ND 8 
21 - - 8 16 ND 16 
23 - - 4 16 ND 32 
31 - 4 4 64 ND 64 
34 - - 4 32 ND 64 
1 - 1QD - - - 8 
2 - ND - - 4 64 
3 - ND - - - 32 
4 - ND 4 - 4 32 2 
6 - ND 4 - 4 4 
7 - ND - - - 64 
8 - ND - - 4 - 
90 - ND 4 - - 64 
11 - ND 4 4 ND 4 
15 - ND - - ND - 
20 - ND 4 4 ND 16 
3 26 - ND - - ND 4 
29 - ND - - ND 4 
33 - ND - 4 ND 8 
37 - ND - ND ND 4 
* Titres cf <4 are considered to be negative 
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In 6 of the lambs in Group 2 treated with antiserum 
(IRA titre 1024), the treatment was reflected by the 
appearance of raised IHA titres(geometric mean = 35.9). 
In 2 other treated lambs, no rise in serum antibody could 
be detected. 
Lymphocyte transformation responses 
The responses of lymphocytes from vaccinated and 
unvaccinated lambs to p. haemolytica are shown in 
Fig. 2.6. Lymphocytes from the unvaccinated control 
lambs (Group 4) did not respond to stimulation with 
p. haemolytica type Al until after challenge when the 
mean S. I. increased to 3.3 and 3.4 on the 3rd and 5th 
days respectively after infection. No response to 
P. haemolytica type Al was observed in lymphocytes 
cultured from 4 of the lambs in Group 1 prior to vaccina- 
tion or 3 days after vaccination. However, by the 7th 
day after vaccination, the mean S. I. was 3.4, and remained 
at a similar level. during the next 4 weeks, until challenge 
with the aerosol of P, haemolytica type Al. Within 
one day of challenge, the mean S. I. had begun to rise, to 
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Clinical responses, microbiology and pathology 
The clinical respcnses, microbiology and pathology of 
these lam s following challenge are summarised in 
Table 2.4. 
Clinical responses 
Lambs in Groups 1,2 and 3, which were infected with 
P13 virus developed the clinical signs of pyrexia, 
dyspnoea, anorexia and dullness described previously in 
association with this infection (Wells, Sharp, Rushton, 
Gilmour and Thompson, 1978). After exposure to the 
aerosol of P. haemolytica,. lambs in the vaccinated group 
showed no further signs of clinical illness except a 
slight pyrexia. This was observed in only two lambs on 
the day after infection with P. haemolytica. In contrast, 
4 of the 7 lambs in Group 3, treated with negative control 
serum were dull and 7 of the 8 lambs in Group 2 treated 
with antiserum to P. haemolytica showed pyrexia and 
dullness during the 5 days following infection with 
P. haemolytica. Dyspnoea was observed only in the 
unvaccinated control and antiserum treated lambs. The 
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in the group treated with antiserum exhibited more marked 
clinical signs than the other lambs in this group and 
both these lambs died on the fifth day after infection 
with P. haemolytica. 
Pathology 
Macroscopic lesions of pneumonia were observed in 
the lungs of 2 of the 8 vaccinated lambs in Group 1,7 
of the 8 lambs in Group 2 and 5 of the 7 lambs in Group 3. 
The extent of lesions present in vaccinated lambs, as 
estimated by planimetric measurement of the drawings 
showing the pneumonic lesions, was significantly less 
(P <0.01) than in Group 2 lambs treated with the antiserum 
and Group 3 lambs receiving negative control serum. There 
was. no significant difference between the extent of 
pneumonic lesions observed in lambs in the antiserum-treated 
group, and those lambs in Group 3. 
Microscopically, the pneumonic lesions observed in 
lambs from all groups were similar to those associated with 
p. haemol. ytica infection (Rushton, Sharp, Gilmour and 
Thompson, Journal of Comparative Pathology, in press). 
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Considering both the results of clinical observation 
and extent of macroscopic lesions, there was no significant 
difference observed between Groups 2 and 3. In contrast, 
the severity of disease assessed in this way in the 
vaccinated group was significantly less (P <0.01) than 
in either the Group 2 or Group 3. 
Microbiology 
P. haemol ty ica type Al was isolated, from pneumonic 
areas of lung in 2 of the 8 vaccinated lambs. By 
comparison, the bacteria were isolated from pneumonic 1-ung 
tissue from 7 of 8 lambs in Group 2 treated with antiserum 
and 5 of 7 lambs in Group 3. Mean bacterial counts 
per gram of pneumonic tissue from these lambs in Groups 2 
and 3 were 10 
7.4 (Range 10 6.0- 10 9.0 ) and 10 
7.1 (Range 10 5.9- 
10 
8'2) 





two vaccinates. P. haemolytica type Al was isolated from. 
apparently normal lung tissue from 4 of the 8 lambs in 
Group 2 (Range 103'7-106.5) and 2 of the 7 lambs in 
Group 3 (103.5,103.7). 
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Discussion 
The phagocytic assay used in Experiment 1 has 
been successful in demonstrating phagocytosis of 
Staphylococcus albus by human granulocytes and mouse 
peritoneal macrophages (van Furth, van Zwet and Leigh, 
1978). In Experiment 1, it is doubtful whether 
phagocytosis by sheep lung wash cells was demonstrated. 
However, sera from immunised lambs had a bacteriostatic 
effect upon P. haemolytica in this system, both in the 
presence and absence of AM. The presence of antibodies 
of the IgG class to P. haemolytica in these sera was 
demonstrated by the ELISA technique (Fig. 2.1). As this 
experiment was performed in vitro, it is difficult to 
assess whether this effect is of importance in the intact 
animal. The apparent failure of lung wash cells to 
phagocytose P. haemolytica may be a reflection upon their 
inability to phagocytose and inactivate P. haemolytica in 
vivo, or, alternatively, the conditions of the experiment 
may not have been optimal for the demonstration of 
phagocytosis. More recent experiments have indicated 
that P. haemolytica has some toxic effect upon sheep AM 
when they are incubated together in vitro under conditions 
similar to those of Experiment 1, which may suggest that 
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sheep AM are unable to phagocytose P. haemolytica 
(Sutherland, personal communication). Benson, Thompson 
and Valli (1978) found a similar cytotoxic effect on 
exposure of bovine AM to live P. haemol. ytica which were 
not readily phagocytosed by the AM. In contrast, heat- 
killed P. haemolytica were phagocytosed to a greater 
extent, and produced only mild cytotoxic changes. 
The SSE vaccine of P. haemolytica type Al has 
previously been shown to'protect against the effects of 
challenge infection with this type (Gilmour, Martin, 
Sharp, Thompson and Wells, 1979). Previously, lambs 
were challenged 2 months after vaccination, and in some 
cases, 2 doses of vaccine were given. In Experiment 2, 
protection was demonstrated one month after a single 
vaccination (Group 1). Control lambs exhibited clinical 
signs of respiratory disease, and at post-mortem pneumonic 
lesions were more extensive than in the vaccinates. A 
vaccine of this type may be of value in the prophylaxis 
of pneumonic pasteurellosis and more extensive studies 
have been carried out with a view to its development 
(Gilmour, Martin, Sharp, Thompson and Wells, 1979). 
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In 6 of the 8 lambs which received antiserum to 
P. haemolytica (Group 2) serum antibody titres were 
similar to those recorded in the vaccinated group (Group 1) 
at the time of challenge (Table 2.3). However, no pro- 
tective effect could be attributed to the antiserum, which 
supports the contention that serum antibody is not the 
only factor involved in protection of lambs against 
respiratory disease associated with P. haemolytica 
infection. Previous experiments have shown that serum 
antibodies are transferred into the secretions of the 
respiratory tract of sheep (Smith, Wells, Burrells and 
Dawson, 1976; Wells, Dawson, Smith and Smith, 1977). 
Consequently, it is unlikely that any difference between 
the 2 groups is due to a difference in the concentration 
of antibody in the secretions bathing the respiratory 
mucosa. 
The antiserum used for passive protection in this 
experiment was raised by hyperimmunisation of lambs, and 
it is feasible that the antibodies produced were not 
protective. The fact that THA titre does not necessarily 
correlate with protection from challenge makes this a more 
likely possibility. This point might be clarified by 
repetition of the experiment using sera from lambs which 
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were recovering from P. haemolytica infection. 
The data from the lymphocyto transformation studies 
showed a specific proliferative response in lymphocytes 
from vaccinates cultured in the presence of P. haemolytica 
type Al SSE. Such in vitro responses to antigens are 
considered to be a measure of cell-mediated immunity 
(CMI) in vivo. It was shown that in patients suffering 
from acute infectious mononucleosis, loss of the cutaneous 
response to tuberculin antigen, which is considered to be 
a measure of CMI, correlated with depression of lymphocyte 
transformation responses in vitro (Mangi, Niederman, 
Kelleher, Dwyer, Evans and Kantor, 1974). Fleer, van 
der Hart, Blok-Schut and Schellekens (1976) demonstrated 
good correlation between responses to PPD in skin tests 
and lymphocyte transformation responses with PPD in healthy 
individuals. The proportion of lymphocytes capable of 
this response appears to increase markedly within a few 
days of aerosol challenge by P. haemolytica type Al. 
This may be representative of a secondary cellular immune 
response of rapid onset, and this could play an'im. portant 
part in resistance to infection. 
lob 
The results of Experiment 1 indicate that serum 
from immunised lambs affects th growth of P. haemol_ytica 
in vitro so humoral immunity carnot be entirely discounted. 
Antibody may play a valuable ancillary role in bacterial 
clearance in vivo. In support of this, it may be 
significant that no antibodies were detected in sera from 
the 2 lambs in Group 2 which died. Humoral immune 
responses are also of major importance in protection 
against the related organism, P. multocida (Woolcock and 
Collins, 1976). 
It can be concluded from these results that monitor- 
ing of circulating antibody may not provide a reliable 
index of the efficacy of vaccines. It would be unwise 
to disregard serological data entirely, since there may 
be some relationship between the humoral immune response 
and CMI induced by vaccination. If CMI responses are 
involved in protection against P. haemolytica then 
clearly some method of evaluating these responses would 
be of value in monitoring potential vaccines. 
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Non-specific resistance to P. haemolytica 
Introduction 
Several Pasteurella vaccines are available commerci- 
ally, yet despite their widespread use, many outbreaks of 
pasteurellosis occur (Veterinary Investigation Diagnosis 
Analysis II Report, 1977). However, it has been suggested 
on occasion by veterinarians that the Pasteurella vaccine, 
Carovax (The Wellcome Foundation Ltd., Beckenham, England), 
administered to sheep during an outbreak of pasteurellosis, 
may reduce mortality within two days. No data are avail- 
able to support these observations; if they are true it 
is possible that by the time an outbreak is recognised, 
that most of the susceptible animals will have succumbed 
to the infection, and the number of deaths started to 
decrease, regardless of vaccine treatment. - Alternatively, 
the vaccine may induce some resistance to infection. 
Protection of such rapid onset is not likely to be the 
result of a conventional immune response. 
This chapter describes an investigation of the possible 
existence of such an effect, using the model of IP infection 
of mice with P. haemolytica developed in Chapter 1. 
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Materials and Methods 
Mice 
C57 black mice, as described in General Materials and 
Methods, were used in all experiments. 
Vaccine 
The vaccine used in this study was Carovax (The 
Wellcome Foundation Ltd., Beckenham, England), which is a 
formolised alum-treated culture of P, multocida types Ii, 
III and IV, and P. haemolytica types A2, T3 and T10. 
Bacteria and challenge of mice 
P. haemolytica type Al, as described in General 
Materials and Methods, was used for challenge infection 
of mice by the IP route. This method of challenge 
infection was similar to that described in Chapter 1, 
except that 5 hours NB cultures were used for preparation 
of the challenge inocula. 
The strain of E. coli, ]3188, is also described in 
General Materials and Methods. Three hundred ml volumes 
of NB, inoculated from fresh blood plate cultures of E. coli, 
incubated at 370C for 18 hours, were used for preparation of 
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challenge inocula. The bacteria were washed twice in 
0.15 M saline, and individual mice were inoculated IP 
with 0.5 ml of appropriate saline dilutions of washed 
organisms. 
Statistical treatment of results 
In Experiments 2,3,4 and 6, viable organism counts 
in the livers of mice were expressed as log10 cfu, and an 
analysis of variance performed, from which group means and 
SED were determined. 
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Experiment Z- The effect of Carovax given to mice 48 hours, 
24 hours and 6 hours prior to challenge upon LD5ýof 
P. haemolytica 
Design of experiment 
One hundred mice were randomly allocated to four 
groups of 25 mice each (Table 3.1). Mice in Group 1 were 
uninoculated controls. Mice in Groups 2,3 and 4 were 
each injected SC with 0.1 ml Carovax 48 hours, 24 hours 
and 6 hours respectively, before IP challenge with 
P, haemolytica in gastric mucin. Five dose levels of 
challenge organisms were given to 5 mice in each group 
4.8_ 8.8 
(10 10 cfu), and deaths were recorded 48 hours later. 
Results 
The results are shown in Table 3.1. Treatment with 
the vaccine at all three time intervals prior to challenge 
caused an increase in LD50. The largest increase was in 
Group 3, when the time interval between vaccine treatment 
and challenge was 24 hours. The LD50 for this group was 
100-fold greater than that of_ the controls, indicating that 
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Experiment 2- Effect of vaccine treatment of mice at 
different time intervals prior to challenge with P. haemo - 
tica on growth of bacteria in the liver 
This experiment was designed to determine whether 
conventional commercial vaccine treatment at various time 
intervals prior to challenge with P. haemolytica retarded 
the growth of organisms in the liver. 
Design of experiment 
Groups of 10 mice were injected 9C with0,1 ml of the 
vaccine on one occasion 14 days, 7 days, 48 hours, 24 hours, 
12 hours and 1 hour before challenge with P. haemolytica 
type Al. The dose regime recommended for Carovax in sheep 
is two Sc injections, given at an interval of 4 weeks, the 
second given at least 2 weeks before the disease is expected 
to appear. Therefore, a further group of 10 mice were each 
injected SC on 2 occasions, at an interval of 4 weeks, with 
O. 1 nil vaccine. 
Each of these groups was challenged IP with P. haemol- 
ytica type Al in gastric mucin at the appropriate time 
interval after vaccine treatment, along with groups of 
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10 untreated control mice. Due to the amount of work 
involved, it was not possible to challenge all groups on 
the same day, and unavoidably the challenge dose varied 
slightly from day to day (mean 
± SE = 107'05±100.9 cfu/ 
mouse). At the time of challenge and 6 hours later, 
5 mice from each experimental group were killed by cervical 
dislocation. 
Results 
Table 3.2 shows the viable counts of P. haemolytica 
type Al recovered from control and vaccinated mice immed- 
iateiy after challenge, and 6 hours later. The bacteria 
multiplied in the livers of control mice, and mice in wMi'l, 
the time interval between vaccine treatment and challenge 
was 1 hour, 48 hours, 7 days, 14 days and the group which 
had been given 2 doses of vaccine. In contrast, when the 
time interval between vaccine treatment and challenge was 
12 hours or 24 hours, viable counts in the livers decreased 
after challenge. Viable counts in the livers of these 
mice and control mice 6 hours after challenge were signifi- 
cantly different (P< Q. OÖ1). . 
The time interval between 
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effect was 24 hours, so this was adopted as a standard 
time interval in further investigations. 
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Experiment 3- Effect of dilution of Carovax on the out- 
come of challenge with P. haemolytica type Al 
This experiment was undertaken to determine the effect 
of dilution of the vaccine with the standard time interval 
between inoculation and challenge of 24 hours. 
Design of experiment 
Groups of 10 mice were each inoculated SC with 0.1 ml 
of a series of 2-fold dilutions of Carovax in PBS, ranging 
from 1/2-1/32 dilutions of the original preparation. One 
control group of 10 mice was inomulated SC with 0.1 ml pBS, 
and another was unt eaLred. The. ým , ýce were chalZcngeý 2z : Acurc 
later IP with P. haemolytica type Al in gastric mucin 
(107.0 cfu/mouse) and viable organism counts were performed 
on the livers of these mice at the time of challenge and 
6 hours later. 
Results 
The results of this experiment are shown in Table 3.3. 
P. haemolytica type Al did not multiply in the livers of 
mice inoculated with undiluted- vaccine, and after dilution 
up to and including 1/4, by 6 hours after infection. Viable 
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were significantly different from controls (P< O. 00l). 
These results indicate that the factor responsible for 
bacterial multiplication was present in a concentration 
too low to be effective when the vaccine was diluted 
further than l/4. 
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Experiment 4- Effect of treatment with individual 
coinponents of the vaccine on the outcome of 
Challenge with P. haemolytica type Al 
Experiment 4 was designed to discover which components 
of Carovax were responsible for the protective effect 
observed 24 hours after injection of the vaccine. 
Design of experiment 
The constituents of the vaccine, without the formoli- 
sed organisms, were kindly provided by Dr. L. K. Nagy of 
the Wellcome Foundation Ltd. The vaccine contains the 
preservative, thiomersal, and either this or the aluminium 
hydroxide adjuvant could have been responsible for the 
protective effects observed in mice injected with the 
vaccine. Placebo vaccines were prepared from the same 
nutrient broth normally used to grow the vaccine strains 
of P. multocida and P. haemolytica, aluminium hydroxide 
and thiorersal. Once placebo contained broth and aluminium 
hydroxide, the other contained in addition thiomersal, all 
at the same concentrations as they appear in Carovax. 
Forty mice were allocated to 4 groups of. 1.0 mice each 
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another received 0.1 ml complete vaccine SC. -A third 
group was injected SC with o. 1 ml of the vaccine constitu- 
ents without preservative, and the fourth group was given 
0.1 ml of the vaccine constituents with preservative. All 
groups were challenged 24 hours later with P. haemolytica 
type Al in gastric mucin (l07'5 cfu/mouse). Five mice 
were killed at the time of challenge, and the remainder 
were killed 6 hours later. Viable counts were performed 
on their livers. 
Results 
The results are shown in Table 3.4. Treatment with 
the complete vaccine resulted in a reduction of viable 
bacterial counts in the livers 6 hours after challenge, 
which was significantly different from the controls 
(P<O. 001). The broth and adjuvant preparation did not 
alter the course of infection with P. haemolytica, regard- 
less of whether the preservative was included. This suggests 
that the factor responsible for reduced bacterial growth is 
not a broth constituent or the adjuvant' contained in the 
vaccine, but is probably one of the bacterial components 
of the vaccine. 
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Experiment 5- Determination of LD50 of E. coli B188 in 
untreate, l mice and in mice treated with vaccine 24 hours 
before challenge 
This experiment was devised to determine whether the 
vaccine would protect mice from challenge with an organism 
not contained in the vaccine. Challenge was by IP infect- 
ion with E. coli. 
Design of experiment 
Twenty-five mice were each injected SC with 0.1 ml 
Carovax. These mice and 25 controls were allocated to 
groups of 5 mice each. E. coli B188 was prepared as 
described in the materials and Mcthcds section of this 
chapter, and 10-fold dilutions were made in 0.15 M saline. 
Five controls and 5 vaccine-treated mice were infected IP 
with each dilution of this inoculum. The number of 
organisms in each challenge dose is shown in Table 3.5. 
Deaths were recorded 48 hours later, and, where possible, 
the LD50 was calculated by the method of Reed and Muench 
(1938). 
Results 
The results are shown in Table 3.5. The LDof 50 
Table 3.5 
Deaths of control and vaccine-treated* mice 
48 hours after IP challenge with E. coli B188 
No of E. coli B188 
given IP per mouse (cfu) 
Deaths in groups of 5 mice 
Contzol Vaccine-treated 
107.4 5 0 
106.4 4 0 
105.4 2 0 
104.4 0 0 
103.4 0 0 
LD50 (cfu) 105.7 > 107.4 
* Carovax 
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E. coli B188 when given IP in saline was 105.7 cfu. Mice 
which had been inoculated SC with 0.1 ml of Carovax 24 hoiz s 
before challenge, did not succumb to the challenge, even 
with the highest challenge dose of 107.4 cfu. Protected 
mice showed no signs of illness. This indicated that 
treatment with Carovax 24 hours previously could protect 
mice from challenge with E. coli, a heterologous organism, 
not present in the vaccine. 
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Experiment 6- Effect of treatment with Carovax 24 hours 
before challenge with E. coli BiC& upon the growth of the 
organism in the livers of mice 
This experiment was designed to determine if treatment 
with Carovax 24 hours before challenge with E. soli B188 
affected the growth curve of E. coli in the livers of mice 
after challenge. 
Design of experiment 
Ten mice were inoculated SC with 0.1 ml Carovax. 
Twenty-four hours later, these mice and 10 uninoculated 
controls were each challenged IP with 107.6 cfu E. coli 
B188 in 0.5 : rl saline, as described in Materials an' Methods. 
At the time of challenge, and 6 hours later, 5 mice from 
each group were killed by cervical dislocation, their livers 
removed aseptically, and viable counts performed on them in 
a manner similar to that described for P. haemolytica 
(Chapter 1, Experiment 6). 
Results 
Viable counts from livers of these mice at the time of 
challenge and 6 hours later are shown in Table 3.6. The 
number of E. coli B188 in the livers of vaccine-treated 
Table 3.6 
Viable counts of E. coli B188 in livers of control mice 
and of mice given 0.1 ml vaccine -+SC 24 Yours before 
challenge IP with 10 
7.6 
cfu E. coli B188 
Hours after 
challenge Control Vaccinate 
5.48* 5.35 
6 7.14 6.07** 
* Mean (log10 cfu) 
SED = 0.284 
+ Carovax 
** significantly different from control (P-', O. OI) 
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mice 6 hours after challenge was significantly different 
from controls (P<O. O1). This indicates that vaccine 




Mice injected SC with Carovax, a Pasteurella vaccine, 
1 hour, 48 hours, 7 days or 14 days before challenge, or 
given 2 inoculations 6 weeks and 4 weeks before challenge, 
were not protected against challenge infection with 
P. haemolytica, using the criterion of growth of organisms 
in the liver after challenge. A protective response, 
manifested by significant reduction in bacterial growth, 
was observed when challenge infection was 12 hours or 
24 hours after administration of the vaccine. It is 
unlikely that this response was due to specific immune 
rechaniss, since it is of such rapid onset and is opera- 
Live over buch a short period of time after administration 
of the vaccine. Mice had not been exposed to P. haemolyttica 
prior to treatment with Carovax, eliminating the possibility 
of a secondary immune response of some kind. Also, no 
response was observed in the group of mice vaccinated on 
two occasions prior to challenge. 
At dilutions greater than 1/4, the effect was abolished, 
suggesting that the active component of the vaccine was no 
longer present in sufficient amount to influence the out- 
come of challenge. In Experiment 4, the reduction of viable 
bacterial counts of P. haemol tica in the livers of 
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vaccinated mice 6 hours after infection was not so marked 
as in Experiments 2 and 3. The challenge inoculum in 
this experiment (107'5 cfu/mouse) was greater than in 





which may explain this discrepancy. Nevertheless, viable 
counts in the vaccinated group of Experiment 4 were still 
significantly lower than the controls, 6 hours after 
infection. The strain of P. haemolytica used for challenga 
of mice was of type Al, which was not a type included in 
the vaccine, yet. a protective effect was observed 24 hours 
after vaccine treatment. There is no evidence in the 
literature to suggest that there is cross-protection 
between types of P. haemolytica,; this indicates that the 
effect may be of a non-specific nature. Further evidence 
was provided by the protection afforded against challenge 
24 hours later with E. coli, which is not a constituent of 
the vaccine. Indeed, the LD50 of E. coli in treated mice 
(10 '4 cfu) is slightly higher than that of P. haemolytica 
in similarly treated animals (107'3 cfu). The observed 
effect is therefore of short duration and is non-specific 
with respect to the challenge organism. There are many 
reports of phenomena similar to this brought about by 
the administration of endotoxin to experimental animals. 
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Among the many effects which bacterial endotoxins exert 
on the body (Elfin and Wolff, 1976) is the stimulation of 
non-specific resistance to bacterial and viral infections, 
similar to that described here. The inoculation of mice 
with bacterial cell walls caused ra&-id changes in 
susceptibility to challenge with E. coli (Rowley, 1956). 
During the first hour after injection of endotoxin, the 
animals were more susceptible to infection, but after 
24 hours a transient state of resistance developed. Non- 
specific resistance of mice to challenge with Staphylococcus 
aureus or Salmonella dublin, after administration of E. coli 
endotoxin, was described by Hill, Hibbitt and Shears (1974A 
and 1974B). 
The vaccine, Carovax, investigated in this study was 
prepared from gram-negative organisms, and it is probable 
that lipopolysaccharide material was present in the vaccine, 
and caused the effect. The mode of action of bacterial 
endotoxins is uncertain, and controversial. The problem 
is further complicated by the fact that the level of non- 
specific resistance induced depends upon the source of 
endotoxin, the dose given, the strain of mouse studied, 
and the strain of micro-organism used for challenge. Mice 
made resistant to the detrimental effects of endotoxin by 
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repeated low doses, killed S. dublin and Staph. aureus 
more rapidly in the tissues than did normal mice (Hill, 
Hibbitt and Shears, 1974B). However, these authors 
could not attribute this effect to increased phagocytosis. 
Wells (personal communication) compared clearance of 
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I-labelled polyvinyl pyrrolidone (PVP) from the blood 
of control mice and mice given Carovax 24 hours previously, 
and detected no difference in clearance rates in the two 
groups. PVP is retained by macrophages and the rate at 
which it is cleared is thought to be an index of macrophage 
function (Morgan and Soothill, 1975). The clearance rate 
is reduced by administration of colloidal carbon or 
hydrocortisone, and increased by oestrogen. Administration 
of Carovax had no effect, suggesting that macrophage function 
may be unaltered by this treatment. In contrast, Benacerr- 
aff and Sebestyen (1957) showed that, within a few hours of 
an Iv or IP injection of endotoxin into mice and rabbits, 
the phagocytic cells of the liver and spleen became less 
effective in clearing injected colloids from the blood. 
This was followed by a period of increased phagocytic 
activity, which was considered to be caused by increased 
production of cells of the phagocytic series. A previous 
tolerising dose abolished the injury caused by a larger 
dose, and caused an almost inimediate*stimulation of 
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phagocytic cells subsequent to a second large dose. 
Using serum from guinea pigs genetically deficient 
in the C4 component of complement, and thus unable to 
support activation of the classical pathway, Frank, May 
and Kane (1973) demonstrated that the components C3 to 
C9 were consumed in the presence of eridotoxin, and that 
endotoxin was able to activate the alternate pathway. 
Evidence has also been presented which suggests that 
endotoxin is capable of activating the classical pathway 
of complement (Fine, 1974). 
It is not evident from the present experiment whether 
p. haemolytica is inactivated within the peritoneal cavity 
more 'efficiently in vaccine-treated mice, and fewer organ- 
isms reach the liver, or whether accelerated killing 
occurs in the liver. In sampling of the liver, bacteria 
both on the surface and within the organ are measured. 
Viable counts in vaccine-treated and control mice at the 
time of challenge are similar, which may suggest that 
comparable numbers of organisms reach the liver, where 
they are more rapidly killed in vaccine-treated mice. 
The vaccine was given by the SC route, so there is no 
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possibility of non-specific stimulation of peritoneal 
macrophages due to the presence of foreign material in 
the peritoneal cavity (Stuart, Habeshaw and Davidson, 1978). 
The experiments described in Uris chapter lend some 
support to the view that Carovax may have some beneficial 
effect in animals infected with P. haemolytica but the 




Further investigations into vaccination and challenge of 
mice with P. haemolytica 
It is essential in the development of a P. haemolytica 
vaccine to gain some knowledge as to which antigens sti. mu- 
late a protective immune response., and also to study the 
existence of any cross-protection between antigens of 
different types. It is only by gaining such an under- 
standing that a logical choice of vaccine strains can be 
made, taking into account the relative frequency of iso- 
lation of particular strains from field outbreaks of disease. 
It is not adequate to vaccinate sheep, and examine the sero- 
logical responses to the various antigens, since the value 
of such data is questionable (see Chapter 2). 
Conventionally reared sheep are unsuitable for study 
of responses to vaccination with P. haemolytica, since most 
sheep have P. haemolytica living as commensals in the 
tonsils or respiratory tract (Gilmour, Thompson and Fraser, 
1974) and have antibody titres to P.. haemolytica (Gilmour, 
personal communication). At present, the most successful 
model by which responses to P. haemolytica vaccines can be 
studied is by vaccination of SPF lambs, followed by chall- 
enge with Pß. 3 virus and P*, haemolyt3. r-a (Sharp, Gilmour, 
Thompson and Rushton, 1978). The cost of screening 
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numerous vaccines composed of various combinations of 
antigens by this method would be prohibitively expensive. 
Also, th. - supply of SPF lambs has seasonal limitations. 
A method for preliminary screening of experimental 
vaccine preparations, before final evaluation in SPF lambs, 
would have many advantages. The use of the SC immuni- 
sation and IP challenge system in mice, described in 
Chapter 1, is investigated in this chapter for the 
screening of vaccines. The advantages of this system are 
that mice are comparatively inexpensive, available through- 
out the year, and that the data obtained gives an indication 
of the resistanc3 to challenge, rather than antibody 
responses. 
The protection afforded by vaccines containing antigens 
from more than one type of P. haemolytica, and the effect of 
vaccinating with one type of P. haemolytica followed by 
challenge with another type, were investigated. Several 
of the vaccines tested in mice were also used in experiments 
using SPF lambs, so it was possible to compare the results 
obtained with the two models of infection. 
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Materials and Methods 
T7-^^I V% m. c! I 
Trivalent (Types Al, A2 and A6) P. haemolytica vaccine 
A vaccine containing three types of P. haemolytica 
was prepared. This vaccine contained SSE of P. haemoly- 
tica types Al and A6, and HKO of P. haemolytica type A2. 
These antigens were individually absorbed onto Alhydrogel 
at optimal dilution, as described previously. The floc- 
culated antigen-Alhydrogel complex was sedimented by con- 
trifugation (500 g, 10 minutes), and resuspended in part 
of its own supernate to one third of the original volume. 
Equal volumes of all three antigens were thoroughly mixed 
together and emulsified with mineral oil, as described for 
monovalent P. haemolytica vaccines. Assuming that all the 
antigen was absorbed onto Alhydrogel, each 0.1 ml dose of 
vaccine contained the following quantities of each antigen: - 
0.019 mg of P. haemolytica type 11 SSE 
0.076 mg of. P. haemolytica type A2 HKO 
0.021 mg of P. haemolytica type AG SSE. 
p, l-iaerolytica type A9 vaccines 
Vaccines containing various combinations of P. haemol- 
4 
133 
ytica type A9 SSE and HKO were also made. These were 
prepared by adsorbing P_ haemolytica type A9 SSE and 
HKO onto Alhydrogel at their optimal concentrations, in 
the manner used for the preparation of monovalent vaccines. 
The flocculated antigen-Alhydrogel complexes were sedimen- 
ted by centrifugation, and aliquots resuspended in appro- 
priate volumes of their own supernates. Mixtures of SSE 
and HKO, at the required concentrations were emulsified 
with mineral oil, as described previously. The con, posi- 
tions of these vaccines are detailed in Table 4.1. 
Challenge of mice with P. haemolytica 
The preparation of inocula for challenge of mice with 
p. haemolytica, and the method of challenge and enumeration 
of bacteria in the livers of infected mice were those 
described in Chapter 1 with the following exceptions. The 
numbers of bacteria present in bacterial suspensions for 
challenge of mice were estimated by measuring their 
absorbance in a colorimeter, as outlined in General 
Materials and Methods. In all the experiments in this 
chapter, NB cultures which had been incubated at 370 C for 
18 hours were used for challenge of mice. 
. 4 
Table 4.1 
Composition of P. haernolyticacype A9 vaccines 
Vaccine 
Weight of P. haemolytica type A9 
antigen in 0.1 ml vaccine (mg) 
HKO SSE 
1 0.114 - 
2 0.114 0.057 
3 0.114 0.284 
4 0.114 0.568 
5 - 0.057 
6 - 0.284 
7 - 0.568 
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Statistical treatment of results 
Viable counts from the livers of mice were expressed 
as log10 cfu, and, where possible, analyses of variance 
were performed. In most of the tables of results, the 
SED is quoted, but in a few cases, the variances were too 
heterogeneous for this to be meaningful, so the individual 
SE is quoted instead. In Experiment 2, some of the results 
were unsuitable for this statistical treatment, and the 






ytica strains for 
of 
C57 
LD values of 
black mice 
LD50 values were obtained for the various strains of 
P. haemolytica by the method described in Chapter 1. 
With the exception of P. haemolytica types A7 and A9, 
in which 10 mice were challenged at each dose level, 
groups of 5 mice were challenged at each dilution of the 
inoculum. 
Results 
The results are shown in Table 4.2. Challenge inocula 
in further experiments were at least 100.5 cfu/mouse grzuter 
than the TD50 Value. 
The LD50 values varied considerably amongst the types 
of P. haemolytica. For types A2, A6 and T3, it was not 
possible to calculate exact values since the lowest challenge 
doses killed more than 50% of the mice. A proportion of 
mice challenged with the lowest doses of each of these three 
strains survived challenge, and it was assumed that the LD50 
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Experiment 2- Vaccination of mice with a trivalent 
(types Al, A2 and A6) P. haemolytica vaccine and challenge 
with types Al, A2, A6 and A9 
It was necessary to discover if all the types of 
P. haemo'lytica must be included in a vaccine for use in 
the field, or if vaccination with one or two types would 
be sufficient to protect from challenge with other types. 
The vaccine used in this experiment contained SSE of 
P. haemolytica types Al and A6, and HKO of P haemolytica 
type A2. Vaccinated mice were challenged with P. haemolY- 
tica types Al, A2, A6 and A9. 
Design of experiment 
Forty mice were each vaccinated twice SC with 0.1 ml 
of the trivalent P. haemolytica vaccine, with a two week 
interval between injections. Two weeks after the second 
injection, these mice and 40 control unvaccinated mice 
were randomly allocated to four groups each consisting of 
10 vaccinates and 10 controls. Each group was challenged 
with one of four types of P. haemolytica namely, Al (107.2 
cfu/mouse), A2 (10 
6.6 
cfu/mouse), A6 (105.0 cfu/mouse), or 
6.6 
A9 (10 cfu/mouse). Five controls and five vaccinates 
in each group were sacrificed at the time of challenge, 
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and the remaining mice were sacrificed 6 hours later. 
Viable counts were performed on liver suspensions. 
Results 
The results of this experiment are summarised in 
Table 4.3. Viable counts in the livers of control mice 
challenged with each of the four types of P. haemolytica 
used in this experiment increased in the 6 hours following 
challenge. Rates of growth similar to those in the livers 
of control mice were observed in vaccinated mice challenged 
with P. haemolytica types A2 and A9, and viable counts in 
the livers of vaccinated mice in these two groups 6 hours 
after infection were not significantly different from those 
of their respective controls. In contrast, over the same 
time interval, viable counts in the livers of vaccinated 
mice challenged with P. haemolytica type Al and type A6 
dropped dramatically. Six hours after challenge, no 
organisms were detected in the liver homogenates of any 
vaccinates challenged with P. haemolytica type Al or A6, 
indicating that their content of viable'organisms was less 
than 10 
2'7 
cfu/ml, the lower limit of the counting technique 
employed. 
Text cut off in original 
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These results show that this vaccine could afford 
protection against challenge with P. haemolytica types Al 
and A6, but not against challenge with types A2 and A9. 
This suggests that HKO of P. haemolytica type A2 may not 
afford protection, even against homologous challenge with 
the same type. Experiment 3 was designed to investigate 
the possibility of successfully immunising mice against 
p. haemolytica type A2. 
139 
Experiment 3- Effect of various vaccination }procedures 
upon challenge of mice with P. haemolytica type A2 
in this experiment attempts were made to protect 
mice from challenge with P. haemolytica type A2, using both 
living and killed preparations. 
Design of experiment 
This experiment was performed in several parts. It 
was thought that the lack of response to P. haemolytica 
type A2 HKO in Experiment 2 may have been due to either 
antigenic competition between antigens in the trivalent 
vaccine, or that insufficient antigen was present in the 
vaccine. Alternatively, P. haemo? ytica type A2 HKO mal not 
bea protective antigen. To investigate these possibilities 
further, two monovalent P. haemolytica type A2 vaccines 
were made, one of which contained 0.227 mg HKO/0.1 ml dose 
of vaccine, and the other 0.682 mg HKO/0.1 ml dose of 
vaccine. The antigens were adsorbed onto Alhydrogel 
and emulsified in mineral oil as previously described. 
a. Vaccination with varying amounts of HKO 
Two groups of 10 mice each were vaccinated SC on two 
occasions with 0.1 ml of these P. haemol tica type A2 HKO 
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vaccines, the second injection being given 2 weeks after 
the first. Two weeks after the second injection of 
vaccine, these mice and a group of control mice were 
each challenged IP with 106.7 cfu'P. haemolytica type A2 
in gastric mucin. Five mice from each group were killed 
at the time of challenge, and five were killed 6 hours 
later. Their livers were removed for enumeration of 
viable bacteria. 
b. Live immunisation 
An attempt was made to protect mice from challenge 
with P. haemolytica type A2 by giving live P. haemolytica 
type A2 in saline prior to challenge. The inocula used 
were 18 hours NB cultures, washed twice in saline and 
resuspended in saline. One group of 20 mice received 
0.2 ml of P. haemolytica type A2 suspension, containing 
107.0 cfu, IP, and another group of 20 mice received the 
same inoculum SC. Eighteen days later, this treatment 
was repeated for 10 mice in each, group. Two weeks later, 
all mice and 10 controls were challenged IP with P. haemoly 
tica type A2 in gastric mucin (10 
6.9 
cfu/mouse). Five 
mice per group were killed at the time of challenge, and 
the remainder were killed 6 hours later. Their livers 
6 
141 
were removed and viable counts performed. 
c. Live immunisation with P. haemolyti_ca type A2 in 
gastric mucin 
In the final part of this experiment, mice were 
infected with a sub-lethal dose of P. haernol tica type A2 
in gastric mucin, prior to challenge with a lethal dose. 
Ten mice were infected IP with 0.5 ml P. haemolytica type 
5.3 
A2 in gastric mucin (10 cfu/mouse). All mice survived 
this challenge. Three weeks later, these mice and 10 
controls were challenged IP with P. haemolytica type A2 
in gastric mucin (10 cfu/mouse). Five mice per group 
were killed at the time of challenge, and the rest were 
killed 6 hours later; viäble counts were, performed on 
their livers. 
Results 
Viable counts of P. haemolytica type A2 in the livers 
of mice given the various vaccination treatments, and their 
respective controls, after challenge with p. haemolytica 
type A2, are shown in Tables 4.4-4.6. The viable counts 
in the livers of mice vaccinated with P. haeniol tica type 
A2 HKO vaccines, or given live p. haumal tica type A2 either 
Key to Tables 4.4 - 4.23 
*** = Viable counts in livers of vaccinates 
significantly lower than controls 6 hours 
after challenge (P<0.001) 
** = Viable counts in livers of vaccinates 
significantly lower than controls 6 hours 
after challenge (P<0.0l) 
* Viable counts in livers of vaccinates 
significantly lower than controls 6 curs 
after challenge (P<O. 05) 
ND = Not done. 
Table 4.4 
Viable counts of P. haemolytica type A2 in livers of 
control mice and mice vaccinated SC with P. haemoiytica 
type A2 HKO vaccines (Experiment 3a) 
VACCINE 
Hours after A2 HKO A2 HKO 
challenge Control (0.227 mg/dose) (0.682 mg/dose) SED 
0 4.69 4.55 3.91 
0.039 ± 0.311 0.312 
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in saline or gastric mucin, prior to challenge, were not 
significantly different from the controls, either at the 
time of challenge or 6 hours later. This indicates that 
the administration of a sub-lethal dose of live P. haemoly- 
tica type A2 is insufficient to protect against challenge 
with P. haemolytica type A2 in gastric mucin. The lack 
of response to P. haemolytica type A2 in the trivalent 
vaccine used in Experiment 1 was not due to either antigenic 
competition, or insufficient antigen in the vaccine, since 
the mice in Experiment 2'did not respond to either of the 
monovalent P. haemolytica type A2 HKO vaccines. 
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Experiments 4-16 - Cross-protection between different 
types of P. haemolytica, investigated by the model of IP 
challenge of mice with P. haemolytica 
Experiments 4-16 were designe' to determine whether 
SSE from the various types of P. haemolytica, when adsorbed 
onto Aihydrogel and emulsified in mineral oil, could be 
used as vaccines to protect mice from challenge with 
P. haemolytica of homologous and heterologous types. The 
designs of these experiments are similar, and are summarised 
in Table 4.7. Groups of. 10 mice were vaccinated SC on 
two occasions with 0.1 ml. of a monovalent P. haemolytica 
SSE vaccine. Two weeks after injection these mice and 
10 controls were challenged IP with P. haemolytica of a 
specified type, in gastric mucin. Inocula were prepared 
as described in Chapter 1, except that the cultures were 
incubated for 18 hours. Viable counts were performed upon 
the livers of challenged mice. 
Results 
The results of these experiments are shown in Tables 































0) O b 
". "I 0 
z 
U 4-I 
"rl O V 
U 





r-1 A (o 4) r-I 04 Ln %. 0 1- OD 0) CA r-I NM d' O 
. c+ U i i 44 i4 r-4 44 rj HH U ' E-4 ýI 
w o o 44 
b 0) (V P4 Un 
CD 
O U N N t o /o tO D N /O 00 rl r-1 
F: 4 4 IC4 0: 4 $4 0: 4 
, 4) % % 000 In Lo Ln Ln %-0 uo Ln OD OD -4 -A r-I l 4 FC ýý FFC ýCFC FCHHH a 
4ý '" N N ('4 N Ln N 0) NW d' d' d' 
0 0 FC FC FC ýC ýC FC FC ýC 0: 4 EH H E+ 
u1 p 
r-i i-1 r-I N r-1 N r-1 r-4 r-1 MMM 
94 FC FC < FC lC 4 FC 4 E+ HH 
4j 
E ä 
















































































UM "K in UO .k am 
.N in 
0 44, 
:1 Co N 
4-) a. 





























r4 ý' 4i 
N r-1 








































"ý1 r co 
U M 
d 
. . . 
tn tO O 
-f'1 N 
d) 
U 0 rn ko U d1 O 
. . . 
Ln r- 0 
+1 
u) 
" r4 Lfl 
u N M r-I 
U O H H 
. . 
Ln N 0 
+1 
d) 
U r-I N Lf1 
U H d' 0 





u r-1 O O 
rte . 




O N co N 
4 C1 01 r-1 
. 
















































































5 in N 
v 
u a) N 













. -a ONN 
$4 M d' 

































































.H 00 U N O O 
U OD cV r-1 





", ý Ln it U d kdý 
U N N . lclD 
+ 
N 
"ý O U Ol in N 
U c" (N in 
. . 





Ü (3'% ri LA O H 
D Ln O N +1 
N 
"rl Co 
U H CO 
U . -1 r-1 l0 
> In O b 
+ý 
I 
O 0 N m $ co O r 
















































































? a) a) 
Lr1 N 
r-t 



































































". -I co My co Ua 
rý U Lo 
tti 
d) 
"r4 ON 0 
U 
ro LI) u 
aý 
"r4 0 r- 1.0 01 r 
F: 4 u ( Ln ui 
C) 
f: 4 U0 5 
Ln 
N 
NU Ll N 
<U cr, kc 
b. 
> Lf) LIl 
., i Lo 
r-1 U Ci u1 
U 
((f lf) U1 
Q rM d' 






































































o ao Q N CO 
1 r4 (f) 
O 0 
u) 










O C m 
.4 ý 1 0 43 























u Ict %D UA in 
co .. 
y l0 I 
N 
U0 d' 
U OD r 
(U . 
9 u1 S 
. -1 
H 
O 0i H 
m O O 




































































"Ü N O N N 
U O m rn 
(d . 




. r4 u1 U Ol rl rl 





U N H 










O . in m 
1"+ r-I N O 4. r . 




































































U to M 









U CO M 
U rm 1.0 











































































u CC) C, 4 





U 0) %D 





U M 0 
Ea 
r-I 
0 %0 id M r4 






H O "D 
N e-1 


















































e O 0 
W O (V) 
0 0 
N 
C) l0 CO 





U N CO 
ro 
> W N 
d' 
u) 
U ýO ýt 
U N N 




O M N 
M 






































d1 (rtf rl 
ri U 4. ) 





































U 0 "x0 d' U M ýO M 
. , . 





". I "k d` U 0) -x ti d' 
U e -x OD O . . . 




"ri 0 U -K Lt) rl U M k 
D ºn r- O +t 
. -i 0 O H M d' 
14 M r 0 


















































N I A A I A I A I A 
z z z z H 
'- ' ' ' r-I z z z z 
z z 
x z 4c z z 
z z z z z 
z z z z 
IC 
z z z 
z z r z z 
' ` ' ' ý r+ Z 
z z z 
IC 
H 
Type of 2, haemolytica in 
monovalent vaccines 
Table 4.21 
Summary of results of Experiments14-16 
Type of P. haemolytica used for challenge 
Iro 
cI ý' y P) oýa'< öým 
N" co 
mr 
Co mft :i N " 
rr n P) 
T3 T4 T10 
T3 - - ** 
T4 - - *** 
T1O - - 
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SSE of P. haemolytica types Al, A6, A8, All and TlO 
protected mice against challenge with the homologous type. 
In addition, both P. haemolytica type Al and type A5 vaccines 
afforded some protection against challenge with P. haemoly- 
tica type P. 3, and the P. haemolytica type T3 and T4 vaccines 
protected against challenge with P. haemolytica type T10. 
SSE of P. haemolytica types A2, A5, A7, A9, A12, T3 
and T4, did not protect mice from challenge with homologous 
types of P. haemolytica. 
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Experiment 17 - Vaccination of mice with P. haemolytica 
type A9 SSE and HKO, and challenge with P. haemolytica 
type A9 
Experiment 17 was designed to investigate the 
possibility of protecting mice against challenge with 
P. haemolytica type A9, using vaccines composed of 
combinations of P. haemolytica type A9 SSE and HKO. 
Preliminary experiments had shown that combinations of SSE 
and HKO of P. haemolytica type A2 in a vaccine afforded 
some protection against homologous challenge (Gilmour, 
personal communication) and this experiment was designed 
to determine whether similar results could be obtained with 
p. haemolytica type A9. 
Design of experiment 
The vaccines used in this experiment contained various 
coiiinations of P. haemolytica type A9 SSE and HKO, and 
their. compositions are detailed in the Materials and Methods 
section of this chapter. Groups of 10 mice were each 
vaccinated SC on two occasions with 0.1 ml doses of 
vaccine. Challenge was with P. haemolytica type A9. in 
gastric mucin, two weeks after the second vaccination 
(107.0 cfu/mouse). 
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Vaccine 2 (see Table 4.1) was retested using a group 
of 25 control mice and a group of 25 vaccinates. Chall- 
enge was with P. haemolytica type A9 (10 
6.8 
cfu/mouse), 
and five mice from each group were killed at the time of 
challenge, and the remaining mice killed 6 hours later. 
Results 
These results are shown in Tables 4.22 and 4.23. In 
the first part of the experiment, the viable counts at 
6 hours after challenge from each group of vaccinated mice 
were compared in turn with the controls by means of a t-test. 
No statistically significant differences were found, partly 
due to variance heterogeneity. Some mice in these groups 
appeared to have responded to vaccination whereas others 
did not. 
Three of the five mice vaccinated with vaccine 2 and 
killed 6 hours after challenge appeared to have responded 
to the vaccine, whereas only two mice in the groups given 
vaccines 3 and 4 responded. For this reason, vaccine 2 
was chosen for repetition of the vaccination and challenge 
with larger numbers of mice. The results are given in 
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Table 4.23 
Viable counts of P. haemolytica type A9 in livers of 
control mice and mice vaccinated with P. haemolytica 
type A9 ("vaccine 2") 
Hours after 




0 5.93 5.95 
6.00 5.98 
x 5.84 5.93 






















SE -0.090 0.302 
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viable counts in the livers of the vaccinated mice, but 
nevertheless the viable bacterial counts in the livers 
of the vaccinated group 6 hours after infection were 
significantly lower than the controls (P<0.001). 
Discussion 
148 
This part of the study investigated the value of IP 
challenge with P. haemolytica and monitoring of bacterial 
growth in the liver as a means of assessing the protective 
value of vaccination with types of P. haemolytica other 
than type Al. The ability of a vaccine containing one 
type of P. haemolytica to protect against challenge with 
another type was also investigated. 
In these experiments, inocula were prepared from 
18 hours NB cultures, and not 5 hours NB cultures which 
were previously used. The viable counts of 18 hours 
NB cultures were variable, but the method for estimating 
the nur')Der of organisms in a susponsion by colorimctry 
proved to be sufficiently accurate that the number of 
viable organisms in 18 hours NB cultures could be confi- 
dently predicted, and these cultures gave equally satisfactory 
results in challenge experiments. 
The SSE antigens in the monovalent vaccines were 
standardised on the basis of dry weight (see General 
Materials and Methods). Since the nature of the component 
active in conferring immunity in the preparations is as 
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yet unknown, the choice of a parameter by which to 
standardise them is difficult, and to some extent arbitrary. 
Another possible criterion is activity of SSE extracts in 
the IHA test, but the value of this is doubtful, as there 
is only limited evidence to suggest that IHA activity of 
the extracts is correlated with protection. In the 
absence of any specific criteria by which to standardise 
vaccines they were arbitrarily standardised on the basis 
of the dry matter content using a standard extraction 
procedure. Although clearly imperfect, such a procedure 
is likely to be a crude measure of the quantity of the 
immunogenic material contained in each vaccine. 
in general, variation between viable counts from the 
individual mice in a group was low at the time of challenge, 
and was greater in the mice sampled 6 hours after challenge. 
This was a consistent finding, which may reflect the ability 
of individual mice to cope with the challenge infection, 
although it should be pointed out that an inbred strain of 
mice was used in these experiments, and-one would have 
expected their responses to be similar. 
There was little cross-protection between the different 
types of P. haemo1ytica, which suggests that the antigens 
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involved in protection may be type-specific, and it is 
possible that all the types, or at least those important 
in causing disease, may have to 'i-)e included in an effective 
vaccine. Successful polyvalent pneumococcal vaccines have 
been produced which contain as many as 12 or 13 serotypes 
(Austrian, 1976). The antigens used to prepare these 
vaccines consisted of capsular material, and the immuno- 
genicity of individual components of these polyvalent 
vaccines was comparable to that resulting from their use 
in monovalent vaccines. In Experiment 2, in which mice 
were vaccinated with a trivalent P. haemolytica vaccine, 
protective responses against challenge with P. haemolytica 
types Al and A6 were observed, indicating that there is no 
competition between these two antigens. This is encoura- 
ging for the development of a multivalent P. haemolytica 
vaccine, and suggests that the development of an immune 
response to one type may not prevent the development of a 
response to other types contained in the vaccine. There 
was no cross-protection between-P. ' haemolytica types Al and 
A6 (Experiments 4 and 7), indicating that the responses seen 
in Experiment 2 were separate responses to the two antigens. 
Smith (1959A) vaccinated mice IV with live P. haemoly- 
tica of both type A and type T strains, followed 9 days 
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later with a dose administered subcutaneously. Mice 
were challenged 12 days after the second dose with 
P. haemolytica of a type T strain in gastric mucin. 
Vaccination with the homologous strain gave strong 
protection, and very little protection was seen with most 
of the heterologous strains. There was some evidence to 
. suggest 
that six out of eight type T strains were related 
immunologically, whereas none of the type A strains gave 
any protection against challenge with the type T strain. 
No success was achieved in protecting mice against 
challenge with P. haemolytica type A2, even when live 
organisms were given prior to challenge. Smith (1959A) 
protected mice from challenge with a type T strain of 
p. haemolytica by giving two doses of living organisms in 
broth. Similar protection against P. haemoi. ytica type A2 
was not observed in the present experiment. P. haemolytica 
type A2 is the predominant type incriminated in pneumonic 
pasteurellosis in the United Kingdom (Thompson, Fraser and 
Gilmour, 1977), and it is imperative that a successful 
vaccine provide protection against this organism. Trials 
with P. haemolytica type A2 vaccines in SPF lambs have met 
with very 1ii: ited success (Gilmour, Martin, Sharp, Thompson 
and Wells, 1979) and it is possible that poor antigenicity 
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may be partly responsible for the widespread disease 
caused by this type. 
The. results of Experiment 17, which investigated 
P, haemolytira type A9 vaccines, are not conclusive. It 
appears that some mice responded to the vaccine, and others 
did not; yet the mice used in this experiment were inbred, 
and theoretically the response should have been uniform. 
The variation may have arisen from technical error. The 
entire experiment was performed by one operator, and the 
variation seen in the vaccinated group is not reflected 
in the controls, which makes experimental error less probable. 
Although statistically significant differences could be 
convincingly dcmionstrated between the vaccinated and control 
group in the second part of the experiment, where the sample 
size was increased, the biological significance of these 
results is difficult to interpret. Further experiments 
have been performed using P. haemolytica type A9 SSE vaccines 
(Gilmour, personal communication). A vaccine containing ten 
times the concentration of SSE used in the present experiment 
gave a high degree of protection. This suggests that 
insufficient antigen may have been incorporated into the 
vaccines used in the present experiment, and that more 
uniform results may have been obtained had a concentrated 
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preparation been used. 
The trivalent vaccine, which contained SSE of P. haem- 
olvtica types Al and A6, and HKO of P. haemolytica type A2, 
was protective against challenge with P. haemolytica types 
Al and A6, but not against challenge with types A2 and A9. 
This finding is in agreement. with data obtained from vacc- 
ination-challenge experiments in SPF lambs using the same 
vaccine and the same strains for challenge (Gilmour, 
Martin, Sharp, Thompson and Wells, ]. 979). In addition, 
monovalent vaccines prepared from P. haemolytica types Al 
and A6 SSE protected SPF lambs from challenge with the 
homologous type. There is evidence for a correlation 
between the protection afforded. by these vaccines in mice, 
and the protection which they gave to SPF lambs challenged 
by the method of Sharp, Gilmour, Thompson and Rushton . (1978). 
This model of challenge infection in mice may therefore 
proved useful in assessment of experimental vaccine pre- 
par_ations, but this can only be confirmed when a greater 
variety of vaccines have been tested in SPF lambs. 
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Development of IRA and ELISA tests for the detection 
of antibodies to P. haemolyiica in sera from 
vaccinated mice 
Introduction 
The experiments described in Chapter 4 demonstrated 
very little cross-protection between the different types 
of P. haemolytica in vaccinated mice. The mechanism of 
resistance to P. haemolytica in this model has not yet 
been determined, and the importance of the humoral immune 
response is not known. There is some evidence to suggest 
that serum antibody alone does not confer on sheep prot- 
ection against P. haemolytica (Chapter 2) but antibody 
may play an important role. and information about sero- 
logical cross-reactivity between strains of P. haemolytica 
could be valuable. The experiments to be described in 
this chapter were devised to determine whether cross- 
reactions occur in the sera of mice vaccinated with the 
various types of P. haemolytica. 
The most commonly used serological test for esti- 
mation of serum antibodies to P. haemolytica in sheep is 
the IHA test (Shreeve, Biberstein anc1 Thompson, 1972), 
but its repeatability has been questioned,. and there is 
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poor correlation between serum antibody titres and 
protection against challenge (Gilmour, personal communi- 
cation). Smith (1959A) devised an agglutination test 
for measurement of antibodies to P. haemolytica in mouse 
sera, but apart from this report, 'rhere is no other 
published information on this subject. The IHA test of 
Shreeve, Biberstein and Thompson (1972) was adapted to 
measure antibodies against P. haemolytica in this chapter. 
The ELISA technique, devised by Engvall and Perlmann 
(1972) has been adapted to the detection and quantitation 
of antibodies to a wide variety of infectious agents. 
The test has been modified to microplates and has been 
shown to be convenient, reliable and highly sensitive. 
ELISA tests have been described for the serodiagnosis of 
rotavirus infection of calves (Scherrer and Bernard, 1977), 
Babesia divergens infections in cattle (Purnell, Hendry, 
Bidwell and Turp, 1976), and bovine brucellosis and hog 
cholera (Saunders and Clinard, 1976). Estimation of 
antibodies to P. haemolytica in sheep sera using an ELISA 
test has been described by Burrells, Wells and Dawson 
(1979) . 
Because of its great sensitivity, an adaptation of 
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this test, to measure antibodies in sera from vaccinated 
mice, and to study the possible existence of cross- 
reactivity between the various types of P. haemolytica 
was developed and is described in this chapter. 
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Materials and Methods 
Preparation and collection of mouse sera 
Antisera to each type of P. haemolytica were raised 
in C57 black mice. 
. 
Groups of 10-20 mice were vaccinated 
SC on two occasions with 0.1 ml of the monovalent 
P. haemolytica vaccines described in General Materials 
and Methods. The second injection was given two weeks 
after the first. Two weeks after the second injection, 
the mice were anaesthetised with CO2 and bled out. The 
blood from each group was pooled, and left to clot. The 
sera were separated, and stored at -200 C in 0.5 ml aliquots. 
Serum from unvaccinated mice was obtained in the same 
manner. 
Indirect haemagglutination assays 
IHA tests were carried out by the method of Burrells, 
Wells and Dawson (1979). To 3 ml of P. haemolytica SSE 
of the required type was added 0.2 ml washed packed HuRBC. 
Due to the presence of bacterial haemolysin, a dilution 
of SSE which had previously been shown to coat the HuRBC 
without causing lysis, was used. After mixing and 
incubation for 2 hours at 370C, the cells were washed 
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twice in PBS, containing 0.5% normal rabbit serum 
(Camercn, 1966) before resuspension in this diluent to 
a concentration of 1%. Test mouse sera were absorbed 
with an equal volume of 50% HuRBC for 1 hour at room 
temperature to remove any non-specific agglutinins, and 
heated at 64.5°C for 30 minutes to inactivate IgM (Reid 
and Doherty, 1971) and remove complement. Two-fold 
dilutions (0.025 ml) were made from 1/8-1/2048 in round- 
bottomed microtitre plates and 0.025 ml HuRBC added to 
each well. The end-point dilutions were those showing 
approximately 50% agglutination. 
Reagents for ELISA test 
The buffers and other reagents for the ELISA test are 
detailed in Appendix 2. 
Micro-ELISA assays 
The technique of the test was basically a microplate 
modification (Voller and Bidwell, 1975) of the ELISA 
technique (Engvall and Perimann, 1972). An appropriate 
dilution of P. haemolytica SSE in 0.05 M carbonate buffer, 
pH 9.6, was used to sensitise the wells of polystyrene 
microtitre plates (type M129A, Dynatech Laboratories Ltd., 
159 
Billinghurst, Sussex). Individual wells were filled 
with 300 µl of antigen solution, and held at 40C over- 
night. Excess antigen was removed by washing the wells 
three times with PBS containing 0.05% Tween 20 (PBS/Tween). 
Sera were not inactivated or pre-treated in any way before 
testing. The required dilutions of sera were made in 
PES/Tween containing 0.02% sodium azide and 300 p1 added 
to each well of the antigen-coated plate. After incu- 
bation for 2 hours at room temperature, the plate was 
washed again three times with PBS/Tween. Dilutions in 
PBS/Tween of enzyme-conjugated rabbit anti-mouse IgG were 
then added (300 p1/well) and incubated at room temperature 
for 3 hours. The plates were again washed with PBS/Tween 
and a 300 pl volume of the enzyme substrate at a concen- 
tration of lg/1 in substrate buffer was added to each well. 
One hour later the reaction was stopped by the addition of 
50 pl of 3M NaOH to each well. Absorbance of each sample 
was read at a wavelength of 400 nm in a colorimeter 
(Vitatron UPS Photometer) fitted with a micro flow-through 
cuvette. Results were recorded as peaks on a chart, 
which corresponded to the absorbance (E). Standardisation 
of antigens and sera are detailed in the preliminary experi- 
ments (Experiments 2 and 3) described in this chapter. 
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Experiment 1- Determination of end-point dilutions for 
mouse sera in IHA tests using hrrrologous and heterologous 
P. haemolytica SSE extracts 
Aliquots of HuRBC were coated with SSE from all 
twelve types of P. haemolytica.. Two-fold dilutions of 
each pool of mouse serum were made, and reacted with each 
of these coated HuRBC. End-point dilutions were recorded. 
Results 
End-point dilutions are shown in Table 5.1. Values 
of <4 were considered negative. Antibody to homologous 
antigen was evoked with Al, T3, T4, AS and T10. In 
addition mice immunised with A2 reacted to T3, with AS 
to A9 and with T3 to T10. These results suggest that 
either a very low response is evoked by the vaccine, or 
that this IRA test is too insensitive to detect the 
antibodies present. 
The ELISA test is reputed to be up to 160 times as 
sensitive as the IHA test (Burrells, Wells and Dawson, 1979) 
and for this reason was developed in an attempt to detect 
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Experiment 2- Preliminary titration of P. haemolytica 
type Al SSE in the presence of immune mouse serum and 
titrations to determine optimal dilutions of conjugate 
A series of checkerboard-type titrations was carried 
out to determine the most suitable dilutions of antigen 
and serum to use in this test. Reaction times were those 
detailed in Materials and Methods, which had been found 
to be optimal in the measurement of antibodies to 
P, haemolytica in sheep sera (Burrells, Wells and Dawson, 
1979) . 
Titration of mouse anti-P. haemolytica type Al serum pool 
against P. haemolyti. ca type Al SSE 
All these ELISA tests were carried out as detailed 
in Materials and methods. 
An initial checkerboard titration was performed to 
determine the dilutions of the mouse anti-P. haemolytica 
type Al serum pool and P. haemolytica type Al SSE which 
gave a value of E in the test closest to 1.0. Dilutions 
of the serum and antigen, in their appropriate. diluents, 
were made (1/20-1/5000). Negative cintrols which lacked 
either antigen or serum or both were included since the 
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enzyme substrate contributes some background colouration. 
In this test, an arbitrary dilution of the conjugate was 
used (1/200). 
Results 
The dilutions of antigen and serum in which the E 
value most closely approached 1 were, when both were 
diluted 1/500 (E=0.90) and at dilutions of 1/200 and 
1/500 respectively (E--0.87). 
Titration of conjugate 
Standardisation of the conjugate was undertaken using 
both of these combinations of dilutions. Mouse anti- 
p. haemolytica type Al sera and control-sera at 1/500 and 
1/1000 dilutions were added to the wells of a microtitre 
plate coated with P. haemolytica type Al SSE at dilutions 
of 1/200 and 1/500, respectively. Serial dilutions of 
conjugate (1/50-1/10000) were prepared and added to the 
wells after the reaction of the antigen and sera. 
Results 
Values of E at 400 nm using various dilutions of 
conjugate are shown in Fig. 5.1. The greatest difference 
Figure 5.3. Determination of optimal dilution of 
alkaline phosphatase conjugated rabbit 
anti-mouse IgG 
0----0 1/500 dilution of mouse anti- 
P. haemolytica type Al serum 
pool 
0-----ý 1/1000 dilution of mouse anti- 
P. haemolytica type Al serum 
pool 
11---ý 1/506 dilution of control 
mouse serum 























between absorbance by the positive and negative sera at 
the same dilution was when the sera and antigen were both 
diluted to 1/500, and the conjugate to 1/200. The 
conjugate was used at 1/200 in all further experiments. 
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Experiment 3- Titrations of sera and SSE antigens of 
P. haemolytica types Al - A12 using conjugate at 1/20G 
dilution to achieve comparable absorbances at 400 nm 
A series of dilutions prepared from each pool of mouse 
sera was titrated initially against homologous SSE antigen 
at an arbitrary dilution of 1/100. The dilution of serum 
which gave an absorbance closest to 0.7 was determined. 
Some of the types did not attain values of E greater than 
0.7, so this value was used to standardise the sera in 
this particular titration. These dilutions were used 
in a further titration to determine the optimal dilution 
of antigen for use with these dilutions of sera. Dilutions 
of each antigen were made (1/50 - 1/2000) and reacted with 
each of the sera at their pre-determined dilutions. 
A final titration was performed, in which the optimal 
dilutions of SSE were used to coat the wells, and reacted 
with a series of dilutions of homologous sera (1/50 - 
1/2000). This titration served to check the previous two, 
and from it the dilutions of both antigen and sera which 
gave absorbances of 0.7 could be determined. 
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Results 
The concentrations of sera and antigens which gave 
values of E of 0.7 are shown in Table 5.2. 
Table 5.2 
Dilutions of SSE extracts and antisera which give 
E=0 . 70 with a 







Al 1/500 1/200 
A2 1/200 1/100 
T3 1/50 1/200 
T4 1/50 1/50 
A5 1/500 1/100 
A6 1/100 1/100 
A7 1/200 1/50 
Aß 1/100 1/200 
A9 1/100 1/100 
T10 1/50 1/200 
All 1/2000 1/50 
A12 1/100 1/100 
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Experiment 4- Determination of the degree of cross- 
reaction between the types of P. haemolytica in the 
ELISA test 
Design of experiment 
In this experiment, all sera and antigens were used 
at concentrations determined in Experiment 3 (Table 5.2) 
which gave a value of E=0.70. Sera against each type 
of P. haemolytica were reacted with antigen of each type. 
Controls which lacked either serum or antigen were also 
included. 
Results 
The values obtained for absorbance at 400 nm were 
corrected for background colouration by subtraction of the 
appropriate control which contained antigen, but no serum. 
These values are shown in Table 5.3. 
An attempt was made to interpret antigenic related- 
ness between strains in terms of the antibody titre ratio. 
The calculation involved was described by Archetti and 
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The geometric mean of the ratios is given by the formula: - 
r=rlxr2 
where 
heterologous titre (strain 2) 
r1 homologous titre (strain 1) 
_ 
heterologous titre (strain 1) 
r2 homologous titre (strain 2) 
The value r measures similarities between serological 
reactions to different strains. When the homologous and 
heterologous titres are equal, r is maximum (ie, 1/1). 
The greater the denominator, when r is expressed as a 
ratio, the greater the difference between two strains. 
Values of 1/r are given in Table 5.4. To simplify 
the table, the denominators of the fractions only have 
been given (ie, the reciprocal of r). The larger the 
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Discussion 
The ELISA technique is becoming increasingly useful 
for measurement of antibodies to a diversity of antigens. 
The particular test used in this chapter was first success- 
fully adapted for use with sheep sera by Burrells,. Wells 
and Dawscn (1979). The technique has many advantages; 
absorption and heating of test sera are avoided, and as 
the test is read photometrically no subjective influence 
is placed upon the results. The volume of serum required 
is extremely small. Sensitivity of the ELISA test is 
equal to that of radio-immunoassay, and up to 200 times 
more sensitive than haemagglutination inhibition or 
complement fixation tests. 
Provided that the reaction times for each test are 
strictly adhered to, the test is reproducible. For 
example, if the reaction between the enzyme and its 
substrate, which gives the colourätion, is allowed to 
proceed for an extra few minutes, the value of E'may be 
significantly raised. There is a slight discrepancy 
between the E value obtained in Experiment 2 for 
P. haemolytica type Al where both antigen and serum were 
diluted 1/500 (E = 0.90), and the value for the same 
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reaction in the following titration in which the 
conjugate was standardised (E = 0.73, Fig. 5.1). 
The dilutions of sera and antigens which gave E=0.70 
in Experiment 3, gave values of E closer to 0.90 in 
Experiment 4. Routine use of this test would require 
inclusion of reference positive and negative sera, to 
enable comparisons to be made between tests. As no 
such comparisons were made here, this was not necessary. 
It is evident from Experiment 4 that cross-reactions 
between the different types of P. haemolytica occur. 
The sensitivity of the test means that cross-reactions 
will be detected which would be missed in a less sensitive 
test such as the IHA test which was shown to be extremely 
insensitive (Experiment 1). The values of r, as calculated 
by the method of Archetti and Horsfall (1950) give a 
measure of the relative relatedness of types. No attempt 
was made to assess the significance of these differences 
as any decisions based on this would be arbitrary. There 
is some suggestion that there is less cross-reaction 
between A and T types, than between the A types with each 
other, or amongst the T types, although there. is still 
considerable cross-reaction between the A and T types. 
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Type All appears to be the least cross-reactive of all 
the types of P. haemolytica. Type A9 seems to cross- 
react strongly with a number of other types of 
p. hsemolytica, such as types Al, A2, A5, A6, A7, A8 and 
A12, and yet no protection against challenge with type 
A9 was seen in mice vaccinated with these other types 
(Chapter 4). 
In Chapter 4, it was shown that very little cross- 
protection occurs between the different types of 
p. haemolytica. The present ELISA test indicates that 
there are antigens in common between the types of 
P. haemolytica, to which IgG antibodies are raised in the 
mouse, which can be detected by this test, but not by the 
iHA test. Several explanations for this are plausible. 
The crude SSE may contain antigens capable of adhering to 
the polystyrene plates used in the ELISA test, which are 
incapable of attaching to HuRBC used in the MA test. 
This would mean that the ELISA test would measure anti- 
bodies undetected by the IHA test. It is possible that 
such antibodies may not be involved in immunity, and that 
their presence is preventing the detection of the antibodies 
important in immunity to P. haemolytica infection. An 
alternative explanation would be that antibodies alone 
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cannot be responsible for protecting mice in the 
vaccination-challenge system, and that some other para- 
meter, such as the stimulation of CMI or peritoneal 
macrophages is involved in resistance to challenge with 
P. haemolytica. The passive tras: sfer of immune serum 
to SPF lambs did not protect them from challenge with 
P. haemolytica (Chapter 2), suggesting that factors 
other than the humoral response were important in 
protection against P. haemolytica infection in sheep. 
Although the model of P. haemolytica infection in mice 
is in many respects unlike that in SPF lambs, it may be 
that the humoral response does not play a major role in 
this model either. This question may be resolved by a 
study of passive transfer of immune serum in mice prior 
to challenge. 
The ELISA test could be useful for monitoring the 
humoral immune response in vaccinated mice. The small 
volume of serum required makes it possible to take serial 
samples from individual mice, and so the response could 
be followed over a period of time. The conjugate used 
here is specific for IgG antibodies, but although it was 
unavailable at the time of these experiments a conjugate 
of rabbit anti-mouse IgM could be produced for measurement 
of antibodies of the IgM class. 
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CONCLUDING DISCUSSION 
This study was undertaken with a view to elucidating 
the mechanisms which are important in the resistance of 
sheep to disease associated with P. haemolytica infection. 
Pasteurellosis of sheep is a sporadic yet widespread disease, 
and sufficiently important to merit development of an 
effective vaccine. The microbiology and pathology of the 
disease are well documented, but surprisingly little is 
known about the immunological aspects. In the development 
of an effective vaccine, a knowledge of the specific host 
defences important in resistance is of value so that 
appropriate tests may be used to evaluate methods of antigen 
preparation or alternatively to monitor antigen batches for 
efficacy. There arc twelve types of P. haemolyLica 
(Biberstein, Gills and Knight, 1960; Biberstein and 
Thompson, 1966), and it is essential to know whether sero- 
logical cross-reactions and cross-protection occur between 
these types, and also whether combinations of antigens of 
several types in a vaccine will be as immunogenic as these 
antigens in monovalent vaccines. 
The most suitable model of infection for study of these 
problems is that of Sharp, Gilmour., Thompson and Rushton 
(1978). SPF lambs are infected intratracheally and intra- 
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bronchially with P13 virus, and 7 days later P. haemolytica 
is given by aerosol. Lesions similar to those of the field 
disease of pneumonic pasteurellosis develop. This model 
was used in the present study of mechanisms of immunity. 
The major drawback of the model is expense, and it was 
necessary to develop an alternative model of p. haemolytica 
infection, and to show that results of experiments with 
such a model bore relationship to results obtained with 
sheep. The work in this thesis mainly describes attempts 
to develop a challenge system in mice. 
This concluding discussion examines the extent to which 
th-e original aims of this study have been realised, the 
questions which remain to be answered, and the type of 
research which may in the future provide additional useful 
information. 
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Mechanisms of immunity to p. haemolytica in sheep 
P. haemolytica is a commensal which resides in the 
naso-pharynx and tonsils of clinically normal sheep (Gilmour, 
Thompson and Fraser, 1974) and yet, for reasons unknown, can 
invade the lower respiratory tract, and often cause fatal 
pneumonia. Since P. haemol_tica is widely distributed among 
flocks, it might be expected that sheep would have some 
natural immunity to the organism, and indeed the majority 
of sheep have circulating antibodies to several types of 
P. haemolytica (Gilmour, personal communication). It may 
be questioned therefore whether circulating antibodies alone 
protect against infection, and if the level of circulating 
antibody is w reliable index of im unity to infection. 
Experiment 2 in Chapter 2, in which passively transferred 
hyperimmune serum failed to protect SPF lambs from challenge, 
casts doubt upon the importance of serum antibody alone in 
protection against P. haemolytica. It was also shown in 
Chapter 2 (Experiment 1) that serum from vaccinated lambs 
had a bacteriostatic effect upon P. haemolytica in vitro. 
Consequently, the role of serum antibody in defence against 
p. haemolytica infection is unresolved. 
Although serum antibody itself is unable to protect 
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against experimental pasteurellosis, it could still play 
an important auxiliary role. It has been suggested that 
P. haemclytica "may be called the animal equivalent of the 
pneumococci in man" (Biberstein, Gills and Knight, 1960). 
Phagocytos4. s and intracellular killing of Streptococcus 
pneumoniae responsible for pneumoccocal pneumonia of man, 
require the presence of both complement and antibody 
(Robbins, 1978). For opsonisation to occur, the antibody 
must be directed against the capsular component of the cell. 
p. haemolytica is an encapsulated organism, and lipopoly- 
"saccharide is a constituent of SSE, although it is not 
yet known whether antibodies are produced against this 
component (Donachie, personal communication). The 
situation may be analogous to that of Strep. pneumöniae, 
but' until the protective antigens of P. haemoiytica have 
been identified, this remains speculative. 
The site of multiplication of P. haemolytica is the 
lung, and the role of local defence mechanisms must be 
considered. Intramuscular vaccination of SPF lambs with 
SSE in adjuvant provides protection from challenge. It is 
unlikely that intramuscular vaccination would stimulate 
production. of antibody in the lung and although the 
transfer of antibody of both IgG1 and IgG2 classes from 
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serum of sheep to nasal secretions has been demonstrated 
(Wells, Dawson, Smith and Smith, 1977), it is not certain 
whether serum derived antibody is present or active in the 
lower respiratory tract in sheep. Pulmonary host defences 
of rabbits immunised with Pseudomonas antigens have been 
studied (Reynolds, 1974) and it was shown that either 
IN or intramuscular immunisation resulted in the appearance 
of antibody in bronchial secretions. Antibody to 
Pseudomonas aeruginosa was measured by agglutination; 
agglutinating activity in the bronchial secretions from 
intranasally immunised rabbits was present in the IgA and 
IgG fractions, whereas in the bronchial specimens from 
intramuscularily immunised rabbits, agglutination was 
confined to the IgG fractions. IgM was not detected in 
bronchial secretions and complement was present only in 
trace amounts. Using an in vitro culture system with 
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rabbit AM and C- labelled organisms it was demonstrated 
that IgG was a more effective opsonin that IgA. Assuming 
that the situation in sheep is similar to that in rabbits, 
it would be expected that IgG would pas$ into the bronchial 
secretions and be available for opsonisation of P. haemol 
tica. 
It was concluded therefore that measurement of serum 
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antibody against P. haemolytica is not a reliable index 
of immunity and that it was necessary to look further at 
other parameters which might give a more accurate 
indication of immune status. 
Although phagocytosis and intracellular killing by AM 
were not demonstrated (Chapter 2, Experiment 1), this does 
not rule out the possible importance of AM in defence of 
the lung against P. haemolytica. The experiment was 
performed in vitro, and the lack of demonstrable phagocytosis 
need not reflect upon the'situation in the intact animal. 
Clearance of P. haemolytica from the lungs of calves has 
been studied (Lopez, Thomson and Savan, 1976), and it has 
been found that the organism is cleared effectively within 
4 hours of exposure. However, exposure to P13 virus 
7- 11 days prior to exposure to P. haemolytica markedly 
inhibited clearance of the bacteria. Studies similar to 
this, performed in sheep, may give insight into the role 
of clearance of P. haemolytica from the lung, and hence 
almost certainly the role of the AM in defence against 
P. haemolytica. The development of a method for obtaining 
samples of AM from infected lambs by lavage would be useful 
in such a study. 
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P. haemol ty ica appears to have a toxic effect upon 
both bovine (Benson, Thomson and Valli, 1978) and ovine 
(Sutherland, personal communication) AM in vitro, and it 
is important to know whether a similar effect occurs in 
vivo. Under normal circumstances P. haemolytica does not 
enter the lung, which is kept free from bacteria by the 
mucociliary system. P. haemolytica only invades the lower 
respiratory tract when these defences are compromised, as 
they might be during a virus infection. If-the proliferating 
P. haemolytica themselves depress the activation of AM it is 
clear that a very delicate balance must exist between the 
multiplying organisms and the host defence mechanisms. It 
is important to know if P. haemolytica can exert a toxic 
effect upon AM in vivo, and a study of this phenomenon and 
the mechanisms by which it operates would contribute greatly 
to knowledge of the pathogenicity of P. haemolytica. 
No marked toxic effects upon'AM were observed when 
the test organisms in the system were P. multocida, Serratia 
marsescceens, Listeria monocytogenes or Staph" aureus (Benson, 
Thomson and Valli, 1978). Antiphagocytic activity by other 
organisms has been reported. Some strains of Bacteroides 
melaninogenicus and Bacteroides-fragil; _s can 
inhibit phago- 
cytosis by leucocytes (Ingham, Sisson, Tharagonnet, Seldon and 
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Codd, 1977) and it is thought that this may be an important 
factor in pest-operative sepsis. This activity is cell- 
associated in contrast to the toxic effect of P. haemolyt. ica 
which can be produced using the supemates of cultures. 
Another interesting phenomenon has been described in 
experimental pneumococcal pneumonia of rats (Ansfield, 
Woods and Johanson, 1977). Bacterial clearance from the 
lung proceeds rapidly in the early stages of infection, and 
then the anti-pneumococcal defences become depressed as 
pneumonia develops. This effect is thought to be selective 
for Strep. pneumoniae; the affected lungs are still able 
to inactivate organisms such as Staph. aureus, and the 
inhibition is caused by accumulation of capsular material 
in the lung. During growth in liquid culture, P. haemol 
tica sheds capsular material into the supernate, a. nd it is 
conceivable that a mechanism similar to that described for 
Stre . pneumoniae may 
be involved in the pathogenisis of 
pneumonic pasteurellosis. 
it was demonstrated (Chapter 2, Experiment 2) that 
vaccinated lambs which were protected from P. hacmolytica 
challenge had elevated lymphocyte transformation responses 
to P. haemolycica SSE, indicating the possible importance 
of CMI in resistance to P. haemolytica infection. The 
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lymphocyte transformation responses of lambs increased 
markedly after aerosol challenge with P. haemolytica, 
reflecting an increase in the proportion of lymphocytes 
capable of responding to the P. haemolytica SSE antigen. 
This increase was greater in vaccinated lambs than in 
controls, and probably represents development of a secondary 
response after challenge. There is every indication that 
lymphocyte transformation responses to P. haemolytica SSE 
antigens may be a useful means of assessing immunity to 
P. haemolytica in sheep. 
The experiments undertaken in Chapter 2, which, examined 
the role of the immune response in resistance to P. haemoly- 
tica went some way to determining the important aspects, 
but clearly many questions remain unanswered. The cell- 
mediated immune response probably plays an important part, 
but its exact role in resistance to P. haemolytica is not 
known, and further study of this is required. 
The ability of sensitised lymphocytes to release 
lymphokines in the presence of P. haemolytica antigens has 
not been investigated. These factors amplify the cell- 
mediated immune response in a variety of ways, including 
recruitment of more lymphocytes, attraction and retention 
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of macrophages at the site of infection, and their presence 
in the lung could be an important part of its defences 
against P. haemolytica. Macrophage migration inhibition 
factor (MIF) is released in vitro in the presence of 
antigens (Valentine, 1974) and it would be of considerable 
interest to determine whether MIF was also released by 
sensitised lymphocytes in the presence of P. haemolytica 
antigens. 
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Models of P. haemolytica infection in mice 
An attempt was made to develop a laboratory animal 
model for the study of P. haemolytica infection, with a 
view to evaluating the efficacy of experimental. vaccine 
preparat-4ons. The model of IN infection of mice with 
P. haemolytica (Rushton, 1978) proved to be unsuitable 
for this purpose, since the organisms were rapidly cleared 
from the lung, and similar lesions could be produced by 
inoculation of dead and living P. haemolytica (Chapter 1). 
This suggests that damage in the lung may be caused by 
the mere presence of bacterial material exerting a toxic 
effect. Such an effect is unlikely to be in any way 
specific and clearly lacks the feature of bacterial multi- 
plication in the tissues which must be an essential part 
of any bacterial pneumonia. 
Enhancement of infections with P. pneumotropica and 
Staph. aureus in the lung can be achieved by prior infection 
with Sendai virus (Jakab and Green, 1972; Jakab, 1974). 
In view of the fact that dead P. haemolyti. ca cause lesions 
in the lung no attempt was made to explore the effect of 
prior viral infection on infection with P. haemol. tica. 
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The advantages and disadvantages of the model of IP 
infection of mice with P, haemolytica in gastric mucin have 
been discussed (Chapter 1). The model is by no means ideal, 
but in view of the fact that P. haemolytica is not a pathogen 
of laboratory animals, it may be the best than can be achieved. 
The model of IP infection of mice with P. haemolytica in 
gastric mucin has proved useful for the evaluation of vaccine 
preparations. It would be imprudent to assume that vaccines 
which protect mice from'IP challenge with P. haemolytica would 
necessarily be effective in protecting sheep from pneumonic 
pasteurellosis. However, results to date are encouraging. 
Several vaccines have been tested in mice (Chapters 1 and 4) 
and SPF lambs (Gilmour, Martin, Sharp, Thompson and Wells, 
1979) in vaccination-challenge experiments. Vaccines 
which protected mice against P. haemolytica infection 
also protected SPF lambs. Vaccines which contained 
antigens of P. haemolytica type A2 gave no protection against 
this type in either model. Too few vaccines have been 
compared in this way to state categorically that the 
behaviour of vaccines in each model is the same, and it is 
necessary to test more vaccines using both systems. However, 
it is reasonable to suggest that the model of IP challenge 
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of mice with P. haemolytica in gastric mucin may be impor- 
tant in the preliminary screening- of potential vaccine 
preparations. 
There are many dangers inheren'- in using a laboratory 
animal model to test vaccines for use in another species, 
especially as, in the present model, the organism is 
non-pathogenic and the host defences must be comprimised 
before infection can be established. There is always the 
possibility that mice may not respond to antigens to which 
sheep are responsive, and the danger that a potentially 
useful antigen may be discarded on the basis of preliminary 
screening in mice. The amount of antigen required to elicit 
an immune response in the mouse bears no relationship to 
the dose required in another species. 
The experiments described in Chapter 4, in which it 
was demonstrated that in general cross-protection between 
the different types of P. haemolytica does not occur, have 
implications as to the type of vaccine required to combat 
pasteurellosis. If it is confirmed in experiments with 
SPF lambs that there is very little cross-protection between 
t1ne types, a vaccine containing antigens from several types 
of P. haemolytica must be developed. Since the incidence 
185 
of types of P. haemolytica varies, all the commonly 
occurring types would have to be included in a vaccine. 
it is possible that after repeated use of such a vaccine 
that the distribution of types of P. haemolytica would 
change, and types previously rare would appear more 
frequently. In such an event, their inclusion in the 
vaccine would have to be considered. The trivalent 
vaccine (types Al, A2 and A6) was tested in both SPF lambs 
(Gilmour, Martin, Sharp, Thompson and Wells, 1979) and 
mice (Chapter 4), and results indicated that the presence 
of other antigens caused no diminution of the protective 
responses to P. haemolytica types Al or A6, suggesting that 
antigenic competition may not be a problem in the development 
of polyvalent P. haemoiytica vaccines. 
All attempts to protect mice from challenge with 
P. haemolytica type A2 were unsuccessful. Type A2 is most 
frequently incriminated in outbreaks of pneumonic pasteure- 
llosis (Thompson, Fraser and Gilmour, 1.977) and a vaccine 
which fails to protect against this serotype would be unlikely 
to be acceptable. Most attempts to protect SPF lambs against 
P. haemolytica type A2 have been unsuccessful (Gilmour, Martin, 
Sharp, Thompson and wells, 1979). 
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Preliminary experiments have shown that some degree 
of protection of mice from challenge with P. haemolytica 
type A2 can be obtained using a vaccine containing 
P. haemolytica type A2 HKO and concentrated SSE (Gilmour, 
personal communication). This suggests that a protective 
antigen is present, albeit in low concentration, and that 
perhaps the HKO contained in this vaccine is either having 
some adjuvant effect, or that protective antigen is also 
contained in this preparation. The solution to successful 
vaccination against this organism may be found through study 
of its individual antigenic components and their properties, 
rather than immunisation with crude extracts such as those 
used in the present study. 
The SSE antigens examined in this study are crude, 
and contain both protein and polysaccharide components 
(Mould, personal communication). Further analysis of 
extracts of P. haemolytica, to determine both the chemical 
composition and immunogenicity of the components, would 
clarify the situation. Purified. extracts would probably 
be available in small quantities, and the production of 
sufficient amounts with which to test immunogenicity might 
pose a problem. The model of SC immunisation of mice 
followed by IP infection with P. haemolytica would be very 
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useful in a study of this type, as only small amounts of 
antigen combined with adjuvant are required for vaccination. 
The model of IP infection of mice with P. haemolytica 
was also ubed to investigate whether the Pasteurella 
vaccine, Carovax, could bestow short-term non-specific 
immunity shortly after its administration (Chapter 3). 
The results suggested that the vaccine could exert some 
influence upon the resistance of mice to challenge with 
P. haemolytica 12 - 24 hours after the vaccine was given. 
A thorough investigation of this phenomenon in SPF lambs 
would involve a large number of animals, as the time course 
of such an event would not necessarily be the same in sheep 
and mice. If such a phenomenon does occur in sheep, 
administration of vaccine during an outbreak would be of 
some benefit, although it is clearly preferable that a 
vaccine confers immunological protection as well. 
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Serological studies 
Exper-Invents in which antibodies in mouse sera were 
measured by the IHA and ELISA tests were described in 
Chapter 5. The ELISA test detected antibodies to 
P. haemolytica in sera which were. negative when examined 
by the IHA test. The IHA test depends upon binding of 
antigenic components to HuRBC, and it is possible that 
some components failed to do this, although they did bind 
to the polystyrene plates of the ELISA test. If this were 
so, antibodies to such components would 90 undetected in the 
IHA test, but would be measured in the ELISA test. An 
alternative possibility might be that the antibodies produced 
were of low valency, and incapable of agglutinating antigen- 
coated HuRBC. Results of the ELISA test would be unaffected 
by this. The volumes of serum required to perform the 
ELISA test are small, and for this reason the technique may 
prove useful for detecting mouse anti-P. haemolytica anti- 
bodies from serial samples of serum. 
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This study has elucidated some of the mechanisms by 
which sheep resist infection with P. haemolytica. it 
suggests that serum antibody alone is not responsible for 
immunity, and that its measurement is not a reliable indi- 
cation of the immune status of the sheep. Cell-mediated 
immunity is probably important in resistance to pasteurell- 
osis, and lymphocyte transformation responses in the 
presence of P. haemolytica SSE antigen reflect the ability 
of sheep to resist infection with P. haemolytica. 
The model of SC immunisation followed by IP challenge 
of mice with P. haemolytica in gastric mucin (Chapter 1) 
has to date given similar results with experimental vaccines 
to the model of infection of SPF lambs with P. haemolytica 
super-imposed upon P13 virus infection (Sharp, Gilmour, 
Thompson and Rushton, 1978). This model of infection has 
proved useful in assessing experimental vaccines, and, 
assuming that there is a correlation between results obtained 
and the behaviour of these vaccines in sheep, experiments 
have implied that there is little cross-protection between 
the different types of P. haomolytica, and also that anti- 
genic competition between different antigens in a polyvalent 
vaccine may not be a problem. This strongly suggests that 
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a successful P. haemolytica vaccine would have to include 
antigens from several types of P. haemolytica, but there 
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Chapter 1: Experiment 6 
Viable counts of P. haemolytica type Al in livers 
and spleens of mice after infection 
Time after Viable counts of P. haemolytica 
infection type Al 







x 5.50 4.73 







x 5.55 5.35 




3 5.88 5.60 
6.20 5.70 
x 6.00 5.56 




S 7.54 7.46 
7.93 7.18 
7.88 7.44 
SE 0.11 0.16 
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Chapter 1: Experiment 8 
Viable counts of P. haemolytica type Al in livers of 
vaccinated and control mice after infection 
Time after 
infection 





0 MV 5.28 
x" 5.44 4.90 




2 5.60 5.26 
5.40 4.08 
x 5.27 4.56 




5.44 3.18 4 
ý2V MV 
3c 6.18 3.90 




6 5.30 4.20 
MV 4.18 
R 7.00 3.72 
SE 0.58 0.28 
MV = Missing value 
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Composition of reagents for ELISA assays 
Antigen diluent - Carbonate/bicarbonate buffer 
(0.05 mol/1, pH 9.6) 0.02% azide 
NaCO3 1.59 g 
NaHCO3 2.93 g 1000 ml distilled water 
NaN3 0.2 g 
Plate washing solution (PBS/Tween) 
0.5 g/1 Tween 20 in PBS 
(Tween 20: Polyethylene sorbitan monolaurate, Sigma Chemical 
Company, Poole, Dorset). 
Substrate buffer 
Diethanolamine 100 ml 
Distilled water 840 ml 
MgC12 (0.5 mmol/1) 0.0475 g 
NaN3 0.2 g/1 
Adjust to pH 9.8 with HC1 at 1 mo1/1 ( --. 60 ml/1) . 
Appendix 2 (ii) 
Substrate 
p-nitrophenyl phosphate disodium (1 g/1) in 
substrate buffer. 
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p-nitrophenyl phosphate disodium: Sigma 104 phos- 
phatase substrate tablets, Sigma Chemical Company, Poole, 
Dorset. Stored at -200 C. Fresh solutions of this 
were made for each test. 
Reaction arrester 
3 mol/1 NaOH. 
Conju ate for ELISA test to detect IgG antibodies against 
P. haemolytica in mouse sera 
IgG fraction of rabbit anti-mouse IgG (Miles 
Laboratories, Slough, England: Cat. No. 65--57-2), 
labelled with alkaline phosphatase, Sigma type VII(Sigma 
Chemical company, Poole, Dorset) by the method of Engvall 
0 
and Perimann (1972) and stored at 4 C. 
21 7 
Appendix 2 (iii). 
Conjugate for ELISA test to detect IgG antibodies against 
P. haemolytica in sheep sera 
A mono-specific pig anti-sheen IgG serum dialysed 
against 0.01 M sodium phosphate buffer, pH7.6, containing 
0.03 M NaCl, was passed through a Whatman DE 52 cellulose 
column equilibrated with the same buffer. The whole 
IgG fraction was collected and concentrated by pressure 
dialysis against PBS to 5 mg/ml. This specific anti- 
sheep IgG was conjugated with alkaline phosphatase, 
Sigma type VII by the method of Engvall and Perlmann (1972) 
and stored at 40 C. 
Antigens 
The antigens used in the ELISA test were standardised 
preparations of SSE, prepared as described in General 
Materials and Methods. 
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A mouse model of Pasteurella haemolytica infection and its use in 
assessment of the efficacy of P haeinolytica vaccines 
li. B. EVANS AND P. W. WELLS 
. 4ninwl 
Diseases Research Association, Muredun Research Institute, 
4uX Gilmerlon Road, Edinburgh 
A method for Infecting mice with Pasleurella hacmo- 
lirica Is described. Mice were inoculated intraperi- 
toncally with P haemolpica incorporated In gastric 
mucin, killed at various time intervals thereafter and 
viable counts of bacteria were performed on liver sus- 
pensions. P haemolytica grew at an exponential rate 
in the livers of normal mice. Mice vaccinated against 
P haemolytica Al were protected against homologous 
challenge and viable counts decreased rapidly in thtir 
livers. Mice given trivalent P haemolytica vaccine 
(types Al, A2 and A6) were protected against chal- 
lenge with P haemolytica types Al and A6, but were 
not protected against challenge with types A2 and 
A9. These results correlate with findings In sheep. 
Materials and methods 
Mice 
Inbred C57 black mice, four to six weeks old, of 
both sexes, were used throughout. 
Bacteria 
The serotype and strains of P haemolytica used for 
challenge of mice are listed in Table 1, together with 
their origin and LDa, for C57 black mice. Bacteria 
were maintained on blood agar plates incubated 
overnight at 37°C then stored at 4°C. 
OVINE PASTEURELLOSIS CAUSES substantial loss every 
year (Veterinary Investigation Diagnosis Analysis 
11 Report 1977). Although commerical vaccines are 
available, much effort is being directed towards 
devising vaccines which are more effective against 
this disease. The recent development of an experi- 
mental model of pneumonic pasteurellosis in specific 
pathogen-free (SPF) lambs (Sharp e1 al 1978) has 
provided a more dependable means of assessing the 
protective capacity of experimental vaccines than 
was previously possible-However, experimentation 
v ith SPF lambs is costly and the number of animals 
available is limited and seasonal. 
A laboratory animal model of infection with 
Pusleurella haentolyyrica would have the advantages 
of relatively low cost and ready availability of 
greater numbers of experimental animals throughout 
the year. P haemol}-rica is not a pathogen of labora- 
tory animals and this has hindered the development 
of a model to study immunity to the organism. Smith 
(19581 de%ised two methods by which true infections 
Hitis P haemol , ica could be established in mice, 
oi: e by iptracerebral inoculation and the other by 
inn., (xritoneat inoculation with granular mucin. 
This paper describes a modification of Smith's 
original intraptritoneal means of infection, and its 
u. e in a-'. escing the efficacy of P hat-molyfica 
accines. 
Determination of LD,. of P haemolytica for CS7 
black mice 
A 300 ml volume of nutrient broth (Oxoid 
Nutrient Broth No 2) was inoculated from a fresh 
blood agar culture of P haemolyrica. The broth was 
incubated for 10h at 37°C, and the bacteria obtained 
by centrifugation at 1000 g for 20 min at 4°C. The 
bacteria were washed twice in 0.85 per cent saline, 
and resuspended in 10 ml saline. A series of 10-fold 
dilutions was made in saline from this suspension 
and a viable count was performed by the method of 
Miles et al (1938). The undiluted suspension and 
dilutions 10-1- to 10-9 were incorporated into a 
5 per cent suspension of hog gastric mucin, pH 7.2 
(ICN Pharmaceuticals), at a ratio of one part 
bacteria to four parts gastric mucin. Groups of 
five mice were inoculated intraperitoneally with 
0.5 ml of each dilution, and the number of deaths 
per group recorded 48 h after challenge. In general, 
no further deaths occurred after this time. The LD, 1 for each strain of P haemolyiica was calculated by 
the method of Reed and Muench (1938). 
Growth of P haemolytica FAI in the livers and 
. spleens of normal mice 
An inoculum of P haemo! y: ica strain FAI (bio- 
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IABLE 1: Serotype and origin of Phaemo/ylica strains used In 
mouse infection tests and LD60 values assessed by death 
48 h after intraperitoneal Inoculation 
P haemol ytica 
Serotype Strain Origin 
L Opo in 
C57 black mice 
logic cfu* 
Al FAI Lung of experimentally 5.3 
infected lamb 
A2 FA2 Lung of experimentally 6.9 
infected Iamb 
A6 FA6 Lung of experimentally 3.8 
infected lamb 
A9 Referred from Edinburgh 5.1 
Veterinary Investigation 
Centre - 
clu =colony forming units 
type A, serotype 1) was prepared as described 
above. A group of 20 mice was inoculated intra- 
peritoneally with 107-' colony forming units (cfu) 
P haemolytica FAI in gastric mucin, using the same 
method as for determination of the LDbo. At time 
intervals of 1,2,3 and 8h after challenge, groups of 
five mice were killed by cervical dislocation, and 
their livers and spleens removed aseptically. These 
organs were individually macerated with 9 ml pep- 
tone water (Oxoid) in a Colworth, stomacher 
(Seward). Serial 10-fold dilutions in peptone water 
were plated out for viable counting by the method 
of Miles et a! (1938). The mean viable count and 
standard error of the mean (SE) for each group was 
calculated and expressed as logo efu. 
Vaccines 
Using the methods of N.. 1. L. Gilmour, D. A. 
Thompson and D. L. Mould (unpublished) capsule 
extract from P haemolytica type Al was prepared 
by extraction with sodium salicylate. Bacteria 
from an overnight broth culture were shaken 
in M sodium salicylate for 3h at 37°C. The bacteria 
were removed by centrifugation and the supernate 
was dialysed for 48 h against dilute phosphate- 
saline buffer (0.02 M sodium phosphate, 0.03 M 
sodium chloride, pH 7.6) at 4°C. The preparation 
was concentrated by ultrafiltration through a 
Diaflo XMIOOA membrane (Amicon): 
The extract was adsorbed onto Alhydrogel (Miles 
1. aboratories) at a concentration determined by a 
titration carried out according to the manufacturer's 
recommendations. This preparation was emulsified 
in an equal volume of Bayol F (Esso) containing 
10 per cent Arlacel A (Sigma). A trivalent vaccine, 
consisting of capsule extract from P hacmoljtica 
type Al, P hacmolt"iica type A6 and heat-killed 
organisms of P huemnh"iica type A2 was similarly 
combined with adjuvant. 
Vur"r"ioution of mire Frith P bacinolylica . 41 capsule 
vurcine und . urh. %, -yru"ft r"luilh"i, e with 
P hacmulylica 
FA l 
Twenty-five mice were each inoculated sub- 
cutaneously with 0.1 nil P hacmolylica Al capsule 
vaccine. Three weeks later, these mice and a group 
of 25 uninoculated control mice were challenged 
intraperitoneallywith 106" cfu P haemolyrlea FAI 
in gastric mucin. Five vaccinated and five control 
mice were killed at the time of challenge and 2,4 
and 6h thereafter. Their livers were removed aseptic- 
ally and viable bacterial counts were determined. 
Ten mice were each given two doses of 0.1 ml 
P hacmolytica Al capsule vaccine subcutaneously, 
with an interval of two weeks between the two inocu- 
lations. Two weeks after the second inoculation, 
these mice and a group of 10 uninoculated controls 
were challenged intraperitoneally with 105-' cfu 
P haemolytica FA1 in gastric mucin. Immediately 
following challenge and 6h later, five mice from 
each group were killed and viable counts were per- 
formed on liver suspensions. 
Vaccination of mice with trivalent P haemolytica 
vaccine, followed by challenge with P haemolytica 
types A1, A2, A6 and A9 
Forty mice were each vaccinated twice subcut- 
aneously with 0.1 ml of the trivalent P haemolynca 
vaccine (types Al, A2 and A6), with a two week 
interval between inoculations. Two weeks after the 
second inoculation, these vaccinated mice and 40 
control unvaccinated mice were randomly allocated 
to four groups, each consisting of 10 vaccinated 
mice and 10 controls. Each group was challenged 
with one of four serotypes of P haemolytica. namely, 
FA1 (107'' cfu per mouse), FA2 (106'41 cfu per mouse), 
FA6(10''0 cfu per mouse) or A9 (101'' cfu per mouse). 
Five control and five vaccinated mice in each group 
were killed at the time of challenge, and the remain- 
ing five vaccinated and five control mice were killed 
6h later. Viable counts were performed on liver 
suspensions. 
Statistical treatment of results 
Viable counts were expressed as log,,, cfu, and 
means and SE were calculated. Where possible, 
Student's i tests were performed and, where the data 
were unsuitable, the Mann-Whitney ranking method 
was employed. 
Results 
LDao of P hacmolytica sn«uins for C57 block mice 
The LD,,, values of P huenmolrtica strains FAI, 


















Hours after infection 
FIG 1: Viable counts (mean ±SE) of P hoemolj'rica FAI in 
liven and spleens of normal mice after intraperitoneal 
inoculation of 10'"' cfu in gastric mucin 
FA2, FA6 and the type A9 strain are listed in Table 
1. In general, mice which succumbed to infection 
were dead or moribund 24 h after inoculation. 
The 
challenge doses of P haemolytica used in subsequent 
experiments were always greater by at least 10°'' cfu 
than the LD. o for each strain. 
Growth of P haemolytica FAI in the livers and 
spleens of normal mice 
The viable counts of P haemolytica FAI in the 
livers and spleens of normal mice are . shown 
in 
Fig I. Each point plots the mean of the counts for 
five livers or spleens, - standard error, expressed as 
log,. cfu. From 2h after infection, growth of 
P haemolviica FAI in both organs was exponential, 
with similar growth rates in each. In most subse- 
yutm experiments, mice were sampled only at the 
time of infection and 6h later, but in the following 
evperiment, additional mice were killed 2 and 4h after 
infection. In order that a greater number of treatments 
could be investigated simultaneously, viable counts 
in li%ers only were examined in later experiments. 
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Gimt'zh of P haemolytica FAl in mire racrimiled 
with P hacmolytica Al capsule rurrine 
Viable counts of P harrnohvira FAl in the livers 
of vaccinated and control mice are shown in Fig 2. 
Viable counts of P hoemolytica FA1 increased ex- 
ponentially in the livers of untreated mice, Whereas 
there was a reduction in the number of viahic 
bacteria in the livers of vaccinated mice. Fi'e 
infected control mice which were not killed all died 
within 19 h. In contrast, five infected vaccinated 
mice appeared healthy at that time and P barmoly- 
lica FAI could not be recovered from their livers. 
Viable counts in the livers of control and double 
vaccinated mice at the time of challenge and 6h 
after challenge are given in Table 2. The mean % fable 
counts in the livers of vaccinated mice 6h after 
infection were significantly lower than those in the 
controls (P -0.008). 
Effect of vaccination of mice with bivalent (Al, A2, 
A6) P haemolytica vaccine upon challenge with 
P haemolytica types A1, A2, A6 and A9 

















FIG 2: Post-challenge viable counts (mean ± SE) in liven of 
control mice and mice vaccinated three Necks previously 
with P haenurli"tica Al capsule vaccine. The challenge 
inoculum was 10'-' cfu in gastric mucin. gi%cn intraperitone- 
ally 
Hours after infection 
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TABLE 2: Post challenge loo, c viable counts (geometric 
mean ± SE) of P haemolyrice FAI In the livers of control mice 
and of mice vaccinated with 
P haemolytica At capsule four 
and two weeks before lntraperitoneel 
inoculation of 106'0 





01 4 72±0.09 4.71±0.06 
6 6.29±0.20 4.20±0.62' 
T 
Significantly lower than control value (P=0.006) I 
Table 3. Viable counts in the livers of control mice 
s 
challenged with each of the four scrotypcs of 
reased in ti i hi 
E 
nc men s exper P haemolytica used in t 
the 6h following challenge. Rates of growth similar 
to those in the livers of control mice were observed 
in vaccinated mice challenged with P haemolytica 
strain FA2 and P haemolytica A9, and viable counts 
in the livers of vaccinated mice 6h after infection in 
the two groups were not significantly different from 
those of their respective controls. In contrast, over 
the same time interval viable counts in the livers of 
vaccinated mice challenged with P haemolytica FAl 
and P haemolytica FA6 dropped dramatically. 
Six hours after challenge no organisms were detected .i in the liver homogenates of any vacciriated mice 
challenged with P haemolytica FA6, or P haemolytica 
FAI indicating that their content of viable organisms . 
°< 
was less than 10='7 cfu/ml, the lower limit of the 4 
counting technique employed. Wt 
+Iý 
Discussion 
The low virulence of P haemolytica for laboratory oY 
animals has hampered the development of a suitable 
laboratory animal model of infection with this 
organism, and it is necessary to include in the chal- 
lenge inoculum substances which effectively increase 
virulence. Gastric mucin was first used to enhance 
the virulence of P haemolytica for mice by Smith 
(1958), although its mode of action still remains un- 
known. Mucin has been shown to be anti-comple- 
mentary in ºitro by Lambert and Ritchley (1952), but 
a comparison of various mucins revealed little 
correlation between antiproperdin activity and the 
ability to promote infection with Escherichia coil or 
Sraphrlococcus aureus (DeWitt 1958). The intro- 
duction of high molecular weight dextran sulphates 
at the time of infection with P haemolytica increases 
virulence to the same extent as gastric mucin but 
related compounds, such as heparin, are less effective 
(Wessman 1967). 
In his original work with intraperitoneal infection 
of mice Nith P lraemolrlica, Smith (1958) merely 
recorded death or survival of challenged mice. In 
the prevnt csNriments, post-challenge numbers of 
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fable organisms in the livers of mice were deter- 
mined. Preliminary studies with experimental vac- 
cines showed insufficient difference in LD, between 
control and vaccinated mice for assessment of the 
efficacy of vaccine preparations (Evans and Wells un- 
published). In the present experiments, post-challenge 
numbers of viable organisms in the livers of mice 
were determined. By using a suitable challenge dose, 
exceeding the LD. o by at least 10°'+ efu, large dif- 
ferences in the abilities of control and successfully 
vaccinated mice to inactivate P haemolytica were 
detected. This criterion for the assessment of the 
efficacy of vaccines would appear to be more sensi- 
tive than that of LD,.. 
Non-specific stimulation of peritoneal macro- 
phages can occur following the introduction of a 
variety of substances into the peritoneum, such as 
serum and mineral oil (Stuart et al 1978). The 
administration intraperitoneally of bovine serum 
albumin (BSA) adsorbed onto aluminium hydroxide 
and emulsified with oil was shown to have a pro- 
tective effect comparable with intraperitoneal vac- 
cinat ion with Phaemolytica Al capsule vaccine (Evans 
and Wells unpublished). However, no such effect was 
observed when this BSA preparation was inoculated 
subcutaneously. For this reason the subcutaneous 
route of vaccination was chosen in preference to the 
intraperitoneal one in these experiments. 
From the results of initial experiments in which 
mice were killed and sampled at frequent time inter- 
vals after challenge, a standard sampling time of 6 It 
following infection was chosen for all subsequent 
work. By that time, growth of the organisms in the 
livers of control mice had become exponential and 
numbers of viable organisms in the livers of success- 
fully vaccinated mice had declined (Fig 2). Vaccina- 
tion times were standardised as four weeks and two 
weeks before challenge. 
Under the conditions described the vaccine con- 
taining P haemolytica type Al capsule extract pro- 
tected mice against challenge infection with P haemo- 
lr rica FAI. This vaccine has also been shown to 
protect SPF lambs against the effect of infection 
with P haemolytica FAI (Gilmour et al 1979). 
The trivalent P haemolytica vaccine, which con- 
lained capsules of serotypes Al and A6 and heat 
killed organisms of serotype A2, was protective 
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against challenge Hith types Al and A6 but not 
against challenge with types A2 and A9. This find. 
ing is in agreement with data obtained from vaccina- 
tion-challenge experiments in SPF lambs using the 
same vaccine (Gilmour er al 1979). It is notable that 
in both species protection was associated with cap- 
sule antigens (types Al and A6) but was apparently 
not stimulated by heat-killed antigens (type A2). 
The results are evidence of a correlation between 
the protection afforded by these vaccines in mice and 
the protection which they give to SPF lambs chal- 
lenged by the method of Sharp et a! (1978). The 
model of infection in mice may therefore prove use- 
ful in assessment of experimental vaccine prepara- 
tions and experiments are being undertaken to 
determine the degree of cross-protection between 
different serotypes of P haemolylica. 
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